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Abstract 
Given that Streptococcus pneumoniae can cause life-threatening 
pulmonary and systemic infection, an apparent paradox is that the bacterium 
resides, usually harmlessly, in the nasopharynx of many people. Humoral 
immunity is thought to be the primary defense against serious pneumococcal 
infection, and we hypothesized that nasopharyngeal colonization of mice results 
in the generation of an antibody response that provides long-term protection 
against lung infection. We found that survival of of C57L/6 mice after intranasal 
inoculation with wild-type serotype 4 strain TIGR4 pneumococci required B cells 
but not T cells, suggesting that nasopharyngeal colonization elicited a protective 
humoral immune response. In fact, intranasal inoculation resulted in detectable 
pneumococcal-specific antibody responses, and protected mice against a 
subsequent high-dose S. pneumoniae pulmonary challenge. B cells were 
required for this response, and transfer of immune sera from i.n. colonized mice, 
or monoclonal antibodies against phosphorylcholine, a common surface antigen 
of S. pneumoniae, was sufficient to confer protection. IgA, which is thought to 
participate in mucosal immunity, contributed to but was not absolutely required 
for protection from pulmonary challenge. Protection induced by i.n. colonization 
lasted at least ten weeks. Although it was partially dependent on T cells, 
depletion of CD4+ T cells at the time of challenge did not alter protection, 
suggesting that T cells did not provide essential help in activation of conventional 
memory cells.  Peritoneal B1b cells and radiation-resistant, long-lived antibody 
vi
secreting cells have previously been shown to secrete anti-pneumococcal 
antibodies and mediate protection against systemic infection following 
immunization with killed bacteria or capsular polysaccharide [1, 2]. We found that 
peritoneal cells were not sufficient for colonization-induced protection, but sub-
lethally irradiated mice largely survived pulmonary challenge. Thus, our results 
are consistent with the hypothesis that nasopharyngeal colonization, a common 
occurrence in humans, is capable of eliciting extended protection against 
invasive pneumococcal disease by generating long-lived antibody-secreting cells.   
vii
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Chapter I. 
INTRODUCTION  
Streptococcus pneumoniae  
Streptococcus pneumoniae, often referred to as pneumococcus, is a 
member of the genus Streptococcus that includes a variety of gram-positive 
cocci. Each coccus is 0.5-1.5 mm in diameter but they are commonly visualized 
in chains or pairs.  Most of the Streptococci are facultative anaerobes and 
catalase-negative, requiring a source of catalase such as blood for growth. 
Because S. pneumoniae produces a green zone of hemolysis around colonies on 
blood agar, it is classified as alpha-hemolytic. In clinical settings, S. pneumoniae 
is often cultured due to its common presence in the human nasopharynx and 
association with nasopharyngeal tract infections. Clinical isolates of S. 
pneumoniae are usually covered with a polysaccharide capsule, the structure of 
which allows for further classification into different serotypes. Over 90 
pneumococcal capsule variants (serotypes) are defined to date [3].  
S. pneumoniae Capsule 
Virulent strains of pneumococcus are encapsulated and studies indicate 
that in some strains, thickness of the capsule is related to virulence [4]. As 
reviewed in [5], the pneumococcal capsule can interfere with host immune 
responses in several ways, such as diminishing the amount of complement 
deposited on bacterial surface, disrupting the interaction between complement 
and receptors on phagocytic cells, and reducing entrapment by mucus. 
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Polysaccharide structures of the capsule vary among strains, allowing the 
bacteria to infect an individual multiple times since the immune system 
recognizes each serotype as a distinct, independent antigen [6].  
S. pneumoniae in Humans: Natural Carriage vs. Invasive Diseases 
S. pneumoniae is a significant pathogen capable of causing infections 
ranging from common sore throat and ear infections to lethal meningitis, 
pneumonia and bacteremia. Each year, pneumococcal diseases claim over 1.6 
million deaths worldwide, especially in the developing countries[7]. In 
industrialized countries such as the USA, S. pneumoniae is the most common 
cause of community acquired pneumonia [8]. Given its ability to cause lethal 
infections, an interesting paradox is that S. pneumoniae naturally colonizes the 
upper nasopharynx of humans without causing any symptoms.  
 Presence of S. pneumoniae in the nasopharynx is very common within the 
human population and this phenomenon is often referred to as carriage or 
intranasal colonization. Rates of pneumococcal carriage vary depending on 
many factors including ethnicity, socioeconomic status and environmental 
factors. Carriage is most common in children; first acquisition can occur as early 
as one month of age [9] and carriage rate peaks at 55% around 3 years of age 
[10]. In developing countries, about 40% of the healthy adults are estimated to be 
S. pneumoniae carriers and this carriage rate can reach up to 95% in children [3].  
Duration of carriage is inversely proportional to age, lasting from five days to 
months and concurrent colonization with two or more serotype is common [11].  
3
 Intranasal colonization is typically transient and asymptomatic. While the 
bacteria use nasopharynx as a convenient niche to promote horizontal spread 
within the human population, carriage can also lead to invasive infection. 
Following intranasal colonization, local spread of colonizing bacteria can lead to 
sinusitis and otitis media, which are very common in children. In addition, 
aspiration of bacteria into the lungs can lead to pneumonia, and subsequent 
invasion into the bloodstream can cause septicemia and meningitis. When 
pneumococi are found in normally sterile sites such as the lungs, brain, and 
blood, the cases are defined as Invasive Pneumococcal Diseases or IPD. 
Notably, invasive diseases are most common in extreme age groups.  The 
following graph, derived from a table in the report from Active Bacterial Core 
Surveillance report, shows that in 2009 in the US, the rates of IPD were between 
30 and 40 per 100,00 in children under 2 years of age. The rates declined 
significantly in older children and into the adulthood before rising again to ~40 per 
100,000 in persons over 65 years of age.  
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This trend of increased IPD rates in certain age group is representative of 
the pattern around the world and poses rather intriguing questions. What protects 
many individuals (especially between age 5 and 50) from invasive pneumococcal 
diseases, and conversely, what are the risk factors that make infants and elderly 
highly susceptible? Two possible mechanisms of protection associated with age-
specific prevalence of pneumococcal disease are the presence of natural 
antibodies and the induction of adaptive immune responses by nasopharyngeal 
carriage.  
Natural Antibody Protection from Invasive Pneumococcal Diseases 
 In murine models of pneumococcal diseases, high titers of pneumococcal-
specific IgM titers are present in sera of naïve mice. Production of these “natural 
IgM” against S. pneumoniae requires expression of CD19, an important regulator 
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of B cell development. CD19 particularly influences the generation of B1 cells, a 
subclass of T-independent B cells that are found in the peritoneal and pleural 
cavities, as well as the spleen. CD19-deficiency is associated with fewer 
numbers of the B1a subset of B1 cells [12]. Decreased numbers of B1a cells in 
the peritoneum correlates with a lack of anti-pneumococcal antibodies in naïve 
mice, suggesting that B1a cells are responsible for making natural antibody that 
recognizes S. pneumoniae [1].  
 Natural IgM responses are directed against at least two prominent 
pneumococcal antigens: capsular polysaccharides and phosphorylcholine, a cell 
wall component common to all pneumococcal strains [1]. Anti-phosphorylcholine 
antibodies in unimmunized mouse serum can protect immunodeficient mice 
against systemic challenge with serotype 3 pneumococci [13]. Together, 
evidence suggests that natural IgM responses can provide a level of protection 
against S. pneumoniae in many individuals. By participating in early defense 
against invading pathogens, natural IgM also allows for the production of induced 
anti-pneumococcal IgM and other isotypes associated with adaptive immune 
responses [14, 15].  
Adaptive immune responses to S. pneumoniae 
 In humans, high titers of pneumococcal specific IgG against many 
pneumococcal polysaccharides can be detected in healthy, unvaccinated adults 
[16]. In experimental human carriage models, serum IgG and IgA against 
capsular polysaccharides as well as pneumococcal surface protein A (pspA) are 
6
elicited upon intranasal colonization [17]. Colonization-induced humoral 
responses to pneumococcal capsule and protein antigens may explain why many 
individuals, after multiple exposures to pneumococcus during childhood, are 
protected from invasive pneumococcal diseases during their middle-age years. 
Nevertheless, such putative colonization-induced protective responses are 
apparently not effective in young children and elderly individuals. Therefore, 
vaccination is highly recommended for these high-risk groups [7]. Current 
pneumococcal vaccines are based on pneumococcal polysaccharides: the 
children’s vaccine is conjugated to a protein carrier to induce T-dependent 
responses while the adult vaccine contains only the polysaccharides and elicits 
T-independent responses.  
T-dependent responses  
  When T-dependent antigens such as proteins enter a host, CD4+ T cells 
recognize the antigens presented by MHC class II molecules and become 
activated. Activated CD4+ T cells can differentiate into various helper subsets 
such as TH17, TH1 and TH2 cells. CD4+ TH cells can then produce cytokines that 
regulate the immune responses and/or participate in activation of naïve B cells.  
 B cell activation by T-dependent antigens such as proteins requires two 
signals: (1) engagement of the B cell receptor (surface immunoglobulin) by the 
protein antigen; and (2) T cell recognition of an antigenic peptide presented by 
MHC-II molecules on the B cell surface that then promotes engagement of CD40 
on B cells with its ligand CD40L (expressed on activated T cells) [18].  
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Interestingly, non-cognate (i.e. one that does not require T cells recognizing the 
same antigen) help is also possible when the MHC-Iike receptor CD1d presents 
glycolipids to iNKT cells, which in turn secrete cytokines for B cell activation [19]. 
Activated B cells then differentiate into short-lived antibody producing cells or 
participate in germinal center reactions, which result in the production of T-cell 
dependent long-lived plasma cells and memory B cells. Traditional memory B 
cells are quiescent and require CD4+ T-cell help for differentiation into 
plasmablasts upon secondary encounter with the antigen.   
The hallmark of T-dependent responses is the formation of post-germinal 
center memory B cells, which have a prolonged life span and respond rapidly 
and efficiently upon secondary challenge. Accordingly, many vaccine approaches 
include a component to induce T-dependent memory responses.  
T-independent responses   
 An alternative second signal for B cell activation by T-independent (TI) 
antigens can be delivered through direct binding of the antigen to an innate 
immune receptor or by extensive crosslinking of membrane IgM by polymeric 
antigen. As a result, TI antigens can induce antibody responses in individuals 
with no T lymphocytes, although the presence of T-dependent antigens (as is the 
case for immunization with whole bacteria) can influence TI antibody responses 
[18]. Marginal zone B cells of the spleen and B1 B cells found in the peritoneal, 
pleural cavities as well as in the spleen can be activated by T independent 
antigens and rapidly generate plasmablasts to produce IgM to provide early 
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defenses against TI antigens [20]. Although traditional post-germinal center 
memory B cells are not generated in the absence of T cell-help, T-independent 
antigens can also provide long-lasting protection. The pneumococcal vaccine 
typically administered to adults is a prime example of protection afforded by T-
independent polysaccharide antigens.   
Pneumococcal Polysaccharide Capsule: Basis for Current Vaccines 
In addition to being an important virulence factor, the capsule is also very 
immunogenic. The ability of capsular polysaccharides to protect against 
pneumococcal disease has been appreciated since the early 20th century [21]. In 
fact, currently licensed pneumococcal vaccines are based on the capsule, and 
include polysaccharides of the pneumococcal serotypes that are most commonly 
associated with disease. The polyvalent vaccine pneumovax-23 (Merck) is 
recommended for persons over 2 years of age, especially if they are 65 and older 
and/or have increased risk factors such as chronic illnesses and asplenia [8].  
An intriguing aspect of pneumococcal polysaccharide vaccines is that they 
are T-independent antigens. Since T-independent responses cannot form 
germinal centers and traditional memory B cells, the mechanisms by which they 
can provide long-lasting protection has puzzled researchers for decades.  
Recently, some studies have provided mechanistic insights into long-
lasting protection offered by T-independent antigens such as pneumococcal 
polysaccharides. In mice, protection following polysaccharide immunization is 
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achieved by engaging at least two populations of lymphocytes: peritoneal B1b 
cells and long-lived plasma cells that home to the bone marrow. 
B1b cells: B1b cells are a CD5-negative subset of B1 cells that are present in 
large numbers in the peritoneal cavity and respond to T-independent antigens.  
The capacity of B1b cells to provide a long-lived, protective antibody response 
was first demonstrated for Borrelia hermsii infection of mice [22]. For 
pneumococcal infection, Haas et al showed that adoptively transferred B1b cells 
are able to protect immunodeficient Rag1-/- mice against S. pneumoniae systemic 
infection following polysaccharide immunization [1]. The protection by B1b cells 
correlated with high titers of capsular IgM and IgG3, and lasted up to 10 weeks 
after immunization.  
Long-lived plasma cells: After initial exposure to antigens, B cells differentiate 
into short-lived plasma cells that secrete antibodies against invading pathogens. 
In addition, to provide long-term protection, they can differentiate into either long-
lived plasma cells or memory B cells. Memory B cells stay quiescent, only 
differentiating into antibody-producing plasmablasts upon antigen re-exposure 
whereas long-lived plasma cells maintain antibody production independent of the 
continued stimulation by antigen and can last the lifetime of an individual [23]. 
While memory B cells are abundant in the spleen, long-lived plasma cells reside 
primarily in the bone marrow and, because they do not require expansion to 
become antibody producing cells, are resistant to irradiation [24]. Recently, it was 
shown that radiation-resistant, long-lived plasma cells are sufficient for protection 
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from systemic S. pneumoniae challenge after immunization with T-independent 
pneumococcal polysaccharides [2].  
Collectively, these studies provide mechanistic insights and rationale for 
widely used polysaccharide vaccines for pneumococcal diseases. Nevertheless, 
the T-independent nature of the vaccine limits its utility. In particular, immature B 
lymphocytes in children do not respond to pure polysaccharide vaccines, and the 
unconjugated polysaccharide vaccines are not administered to children under 
two years of age.  
Shortcomings of Polysaccharide Vaccines: Rationale for Considering Other 
Pneumooccal Antigens 
 One important limitation of the current vaccines is that they protect against 
only the subset serotypes that are included in the vaccines. Since there are over 
90 pneumococcal serotypes in nature, the vaccines cover only a small fraction of 
the potential pneumococci. With the widespread use of the vaccines to prevent 
infections with certain serotypes, serious diseases are now increasingly caused 
by non-vaccine serotypes, a phenomenon referred to as serotype replacement 
[25, 26]. Accordingly, an important area of research is to better understand the 
immunogenic properties of conserved structures and proteins that would protect 
against all pneumococcal serotypes. Some of the best-studied virulence factors 
include cell wall proteins such as pore forming toxin pneumolysin (Ply), 
pneumococcal surface protein A (PspA), which prevents binding of C3 onto 
pneumococcal surfaces, and pneumococcal surface protein C (PspC), which 
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interferes with polymeric Ig receptor functions (reviewed in [5]. Immunization with 
these antigens [true?] have been shown to elicit robust immune responses in 
humans, and protect mice against systemic infection [27, 28]. Alternatively, a 
whole-bacterium approach that elicits responses to multiple pneumococcal 
antigens can protect against subsequent colonization and disease [29, 30] Both 
protein-based whole-bacterium strategies are being tested for next-generation 
vaccines (summarized in [31]).  
 
Mouse Models of Pneumococcal Disease 
The mouse is the most commonly used animal model for S. pneumoniae 
infection, and is representative of human pneumococcal infections in many 
aspects. For example, similar to humans, mice are susceptible to colonization 
with multiple strains of S. pneumoniae and each colonization can last several 
weeks [31]. In addition, immune responses of mice against invading 
pneumococci have been shown to be applicable to humans in many studies [4]. 
Nevertheless, the mouse model suffers from several limitations: 1) 
serotypes that are able to cause invasive infections in mice do not always 
correspond to those most virulent or prevalent in humans [4]; 2) a wide range of 
infectious doses used for infection in mice makes the interpretation of the results 
more complicated; and 3) most importantly, host immune responses and 
susceptibility to pneumococcal infection varies depending on the mouse strain 
[32].  
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In addition to these caveats that are common in any mouse model of 
disease, S. pneumoniae poses another level of complexity due to its ability to 
infect various tissues with different severity. Studies have shown that relative 
importance of virulence factors are different in various tissues [33], and a 
protective host response could similarly require different tissue-specific cellular 
and effector mechanisms. For example, protective mechanisms that prevent 
asymptomatic colonization may be markedly different from those that protect 
against potentially lethal meningitis. Similarly, local responses in the lung to 
control pneumococcal pneumonia may utilize a set of factors completely distinct 
from what is required to clear bacteria from the blood. Therefore, the mode of 
immunization and the route of infection are important considerations when 
evaluating protective mechanisms against S. pneumoniae. The most commonly 
used immunization and challenge models and their key features can be 
summarized as follows.  
I. Systemic immunization and challenge models 
Mice are commonly immunized intraperitoneally (i.p.) or subcutaneously 
(s.c.) with antigens of interest (e.g., heat-killed whole bacteria, polysaccharides 
or proteins) and challenged i.p. with live pneumococci. Immune responses are 
usually evaluated by serum antibody responses and protection from an otherwise 
lethal i.p. injection. In these models, antibodies are considered essential to 
protective immunity. Immunization with purified polysaccharides leads to 
antibody responses against the pneumococcal capsule and protects mice from 
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subsequent systemic infection [1]. Similarly, immunization with heat-killed 
pneumococci protects against lethal systemic disease by exposing the host to 
not only the capsule but also other pneumooccal surface antigens and eliciting 
protective antibodies [34, 35]. 
Systemic immunization with conserved structures and protein antigens can 
also elicit robust serum antibody responses and protection from subsequent 
systemic challenge. For example, immunization with various pneumococcal 
proteins protects against lethal infection in mice, and protection can be enhanced 
by combining two or more protein antigens [27, 36]. Passive transfer of immune 
sera against pneumococcal proteins is protective [37], suggesting that antibodies 
are sufficient for systemic protection following immunizing with pneumococcal 
proteins.  
 
II. Intranasal (i.n.) immunization models 
Intranasal immunization models may be desirable for mucosal pathogens 
such as S. pneumonaie. In these models, killed pneumococci or pneumococcal 
antigens (most commonly proteins in soluble form or expressed from viral 
vectors) are delivered into the nasopharynx. Within the intranasal immunization 
model, studies can be further categorized based on the route of subsequent 
challenge. Remarkably, even with the same method of intranasal immunization, 
protective mechanisms can be different depending on route of challenge.  
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II.A Protection from systemic disease: Intranasal inoculation with heat-
killed S. pneumoniae prevents systemic disease that correlated with robust IgG 
and IgA responses. Similarly, i.n. immunization with pneumococcal surface 
protein A (PspA) produced antibody-mediated protective responses against 
otherwise lethal i.p. challenge. [38]. Robust IgG responses correlated with 
protection with mice from lung infection following i.n. immunization with 
adenovirus-vectored vaccine harboring three pneumococcal proteins [39]. 
Collectively, these studies suggest that antibodies are important to protect 
against invasive infection following mucosal immunization with heat-inactivated 
bacteria or pneumococcal proteins.  
II. B. Protection from colonization at the nasopharynx:  Intranasal 
immunization with heat-killed unencapsulated bacteria with cholera toxin 
adjuvant prevents colonization [29]. Interestingly, after i.n. immunization with a 
mixture of three purified pneumococcal proteins [40] CD4+ T cells are required for 
protection against colonization of the nasopharynx. Although CD4+ T cells are 
best known for their cognate help during B cell activation and recall memory 
responses, their role in protection in this study was independent of antibodies. 
Instead, it correlated with higher level of IL-17A production, suggesting that CD4+ 
T helper cells that produce IL-17A (TH17 cells) may be important. 
III. Intranasal colonization models 
In order to mimic natural colonization in human nasopharynx by S. 
pneumoniae, an intranasal colonization model in adult mice was developed. In 
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this model, live pneumococci is given in a small (maximum 10ul, divided equally 
between the nostrils) volume into the nostrils to establish stable colonization of 
the nasopharynx without causing invasive pulmonary infections [41]. 
Experimental colonization is similar to natural carriage phenomenon in that it is 1) 
asymptomatic and limited to the nasopharynx 2) self-limiting with colonization 
period around 3 weeks and 3) observed with many serotypes common in human 
diseases. A number of studies have used a modified version of this intranasal 
colonization model to study subsequent protection against mucosal challenge.  
III.A. Colonization with attenuated strains: Intranasal inoculation with S. 
pneumoniae strains that are deficient in one or more virulence factors but still 
retains their ability to stably colonize the nasopharynx has been shown to elicit 
protective responses. After intranasal colonization with capsular mutant, 
pneumolysin-deficient or pneumococcal surface protein A (PspA)-deficient 
pneumococci, significant amounts of serum IgG and mucosal IgA were detected, 
and mice were protected against subsequent re-colonization of the nasopharynx 
or sepsis after by aspiration of bacteria into the lungs. This protection required 
both antibodies and CD4+ T cells because antibody-deficient µMT mice or MHC-
II deficient mice were not protected [30]. Similarly, intranasal colonization with a 
pneumolysin-deficient S. pneumoniae strain afforded protection from subsequent 
carriage and aspiration pneumonia and sepsis. Protection correlated with anti-
capsular IgM and mucosal IgA, anti-PspA serum IgG, and increased levels of 
IL17A and CD4+ T cells in the lungs. The use of outbred mice in these studies 
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precluded a straightforward genetic test using knockout mice to determine the 
role for antibodies or CD4+ T cells (Richards, Ferreira et al. 2010) 
III.B. Colonization with wild-type pneumococci: Upon nasopharyngeal 
colonization, wild-type pneumococci, unlike attenuated strains, require antibody-
independent mechanisms of protection from re-colonization at the nasopharynx 
[42, 43]. Although protection against nasopharyngeal colonization induced by 
prior exposure correlates with antibodies against conserved pneumococci 
antigens, the absence of antibodies in µMT mice does not compromise 
protection. Depletion of CD4+ T cells at the time of challenge, however, abolishes 
protection, suggesting protection was CD4+ T cells mediated [42]. The ability of 
antigen-specific T cells to elicit TH17 responses is required for protection, and in 
fact immunization with pneumococcal proteins recognized by TH17-expressing 
CD4+ T is protective against colonization at the nasopharynx [31, 44]. TH17 
responses likely mediate the protection by efficient recruitment of macrophages 
and neutrophils to the mucosal surfaces during primary and secondary infections 
by S. pneumoniae [45] 
 Taken together, these studies suggest that protection mechanisms vary 
depending on the route of immunization, site of challenge and in cases with live 
pneumococci, the properties of the colonizing strain. Therefore, they highlight the 
need for models of pneumococcal diseases to better reflect natural infections in 
the human population.   
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Intranasal colonization (carriage model): A Tool to Understand Natural 
Infection and Protection 
 Epidemiologic evidence suggests that natural carriage in humans may 
protect many individuals against serious infections. If protective responses 
develop upon intranasal colonization by S. pneumoniae, it will be important to 
understand the cellular and effector mechanisms and incorporate them in future 
preventative measures. Given the evidence that immunization and challenge 
route can influence protective outcomes, we wished to establish a murine 
intranasal colonization model utilizing a wild-type pneumococcal strain that might 
mimic natural carriage and the putative resulting protection in humans. Since 
pneumococcal pneumonia is the most common form of S. pneumoniae disease 
[7], intratracheal inoculation would be an attractive primary means of challenge. 
Such a model might be utilized to explore the nature of the antibody responses 
that recent mouse studies with attenuated strains have suggested are important 
for protection from subsequent systemic disease after challenge with wildtype 
bacteria. In addition, it can be useful to determine whether T cells that have been 
implicated in protection against nasopharyngeal re-challenge are also important 
to prevent invasive diseases. Our current study investigates whether protective 
responses are elicited upon intranasal colonization and identifies some of the 
important features of the response.  In particular, the studies described in this 
thesis address the following specific aims: 
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1) Determine if intranasal colonization results in protection from subsequent 
intratracheal challenge, and whether protection is dependent on the 
capsular serotype. 
a. Are pneumococcal-specific antibodies produced after intranasal 
inoculation? 
b. Are antibodies necessary and/or sufficient? 
c. What is the relative importance of IgG vs. IgA? 
2) Determine whether protection is T-independent, as is the case for 
conventional polysaccharide vaccines, or T-dependent. 
a. Are T-cell deficient TCRβδ-/- mice protected? 
b. Are CD4+ T cells required for protection? 
3) Determine if protection is long lasting and identify lymphocytes that 
mediate such a response.  
a. Are protective antibodies still present long after colonization? 
b. Are long-lived plasma cells sufficient to confer protection?
19
  
Chapter II.  
INTRANASAL COLONIZATION BY SEROTYPE 4 STRAIN S. PNEUMONIAE TIGR4 INDUCES 
PROTECTIVE IMMUNE RESPONSES AGAINST INTRATRACHEAL CHALLENGE.  
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Abstract 
 Nasopharyngeal colonization by S. pneumoniae is very common in 
humans and may function as a natural immunization that results in protection 
from serious pneumococcal infections, including lung infection, the most common 
form of invasive pneumococcal diseases. In order to model the immunological 
effects of nasopharyngeal colonization, we intranasally (i.n.) inoculated mice with 
the serotype 4 pneumococcal strain TIGR4.  Wild-type mice were able to prevent 
lethal disease whereas mice deficient in B cells or in the ability to generate IgM 
were not. Anti-pneumococcal IgM and IgG significantly increased after two 
rounds of i.n. inoculation of wild-type mice, and three i.n. inoculations at one 
week intervals induced protection against a high dose intratracheal challenge 
that is lethal in naïve mice. The magnitude of the antibody response varied with 
the mouse strain, and i.n. inoculation of BALB/c mice resulted in protection from 
i.t. challenge more efficiently than inoculation of C57BL/6 mice. These results 
indicate that nasopharyngeal colonization of mice by wild-type pneumococci is an 
immunizing event that results in protection from otherwise lethal pulmonary 
challenge.   
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Introduction 
Intranasal colonization (i.n.) by Streptococcus pneumoniae is a common 
occurrence within the human population; every individual likely carries this 
bacterium in the nasopharynx at least once in their lifetime [46]. In developing 
countries, up to 95% of children and 40% of adults are carriers of S. pneumoniae 
[3]. Though i.n. carriage is usually asymptomatic, it can progress to cause local 
disease such as sinusitis and otitis media as well as cause invasive infections 
such as pneumonia, bacteremia and meningitis [5]. Invasive pneumococcal 
diseases are most common in children under 2 years of age or persons over 65 
years old [47], leading to the hypothesis that a majority of the human population 
are protected from serious diseases as a consequence of natural colonization in 
the nasopharynx.  
Anticapsular antibodies found in the serum of healthy, unvaccinated adults 
have been the explanation for relatively low risk of serious pneumococcal 
diseases in middle aged individuals [16]. However, recent evidence suggests that 
antibodies to noncapsular antigens as well as antibody-independent cellular 
immune mechanisms may contribute to age-specific decline to pneumococcal 
diseases [6]. In experimental human carriage models, serum IgG against 
pneumococcal surface protein A (PspA) and choline binding protein A (CbpA) are 
detected after i.n. colonization [17, 48]. While the exact mechanisms are unclear, 
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the possibility of protective responses following i.n. colonization remains 
attractive and supported by epidemiologic evidence.  
With the development of nasopharyngeal colonization model in adult mice, 
it is possible to test whether i.n. carriage with wild-type pneumococci elicits 
immune responses that protect from subsequent colonization or disease [41]. In 
this model, i.n. inoculation with low (<10ul) volume of S. pneumoniae can result 
in stable colonization that is confined to the nasopharynx and remains 
asymptomatic in immunocompetent mice. Although studies have shown that 
protective responses against invasive diseases can be achieved by single i.n. 
inoculation [30, 49], there is evidence that multiple rounds of i.n. inoculation can 
enhance protective responses [29, 30]. Indeed, establishment of protective 
responses by i.n. colonization may depend on the immunogenicity of the 
colonizing strain as well as host factors [32].  
In order to generate protective responses as a consequence of 
nasopharyngeal colonization, the host must first be able to limit the carriage to 
the upper nasopharynx and prevent potentially lethal invasive diseases. It is 
currently unclear if adaptive immunity is required to control nasopharyngeal 
colonization to the local site, and if so, which arm(s) of the immune response are 
most critical. In humans, splenectomized or functionally asplenic individuals are 
at increased risk for invasive pneumococcal diseases [50, 51], suggesting that 
lymphocytes located in the spleen and/or the filtration function provided by that 
organ may be important to prevent invasive infections.  
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In this study, in order to evaluate protective responses following i.n. 
colonization, we first determined whether wild-type mice, or mice deficient in 
different aspects of adaptive immunity, could resist lethal infection upon i.n. 
inoculation. We then established a model of i.n. colonization and showed that 
depending on the number of i.n. inoculations, the magnitude of the challenge 
dose, and mouse strain, nasopharyngeal colonization resulted in protection 
against subsequent i.t. challenge.  
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Materials and Methods 
Mice 
 All animals were housed in a pathogen-free facility at the University of 
Massachusetts Medical School (UMMS) and maintained according to the 
standards and policies of Institutional Animal Care and Use Committee. Mice 
were 8 to 10 weeks old at the time of colonization, and include both sexes. Wild-
type C57BL/6 and BALB/c mice were purchased from Jackson Laboratories or 
Charles River Laboratories. C57BL/6J-Rag1tm1 Mom (Rag1−/−), mice that lack the 
secreted form of IgM but have the membrane-bound form of IgM (sIgM-/-) on 
129Sv background, TCR β-chain- and TCR-δ-chain-deficient (TCR βδ-/-) mice on 
a C57BL/6 background have been previously used in our laboratory [52] and 
were bred and maintained in our colony at UMMS. Antibody-deficient µMT-/- were 
from the colony of Dr. Rachel Gerstein (UMMS) and were originally obtained 
from Dr. Klaus Rajewsky at Immune Disease Institute of Harvard Medical School.  
 
Bacteria 
The bacteria were grown overnight on tryptic soy agar plates supplemented with 
5% sheep blood (Northeast Labs; P1100). The colonies were then washed off 
the plates with 1mL of Todd Hewitt Yeast Broth (THY) and grown in THY+5ul/mL 
of oxyrase® (Fisher catalog # 502005299) in 37oC 5% CO2. Bacteria were 
harvested at OD600=0.8 or ~5.0x108 CFU/ml (late log phase). Serotype was 
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confirmed by quellung reaction with capsular serotype-specific antibodies, and 
aliquots were prepared by combining the culture with equal volume of 50% 
glycerol in THY broth (final concentration = ~2.5x108/mL in 25% glycerol). The 
aliquots were frozen at 80o C until further use. Each frozen tube was thawed and 
the bacteria were washed 3 times with 1x PBS and resuspended in 250ul of 
1xPBS (=107CFU/10ul inoculum) for i.n. inoculation or diluted in 5mL of 1xPBS to 
~4x107/mL (=2x106/50ul inoculum) for i.t. challenge. The size of each inoculum 
was confirmed by plating serial dilutions. Serotype 4 strain TIGR 4 and serotype 
2 strain D39 were kind gifts from Dr. Andrew Camilli at Tufts University Sackler 
School of Biomedical Sciences. Serotype 19A strain Hungary (ATCC-700673) 
was purchased from ATCC. Serotype 14 strain has been previously described 
[53] and was a kind gift from Dr. Marc Lipsitch at Harvard School of Public 
Health.  
 
 
Animal Infections 
Intranasal Inoculation (i.n.): Mice were restrained without anesthesia and given 
10ul (107 cfu) of bacteria equally distributed between the nostrils with a pipette. 
Doses were confirmed by plating serial dilutions of the inocula. This procedure 
was repeated to establish i.n colonization where indicated. 
Intratracheal Challenge (i.t.):  Lethal lung infections were given by i.t. 
inoculation at three weeks after the last i.n. inoculation. Mice were lightly 
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anesthetized with Isoflurane (USP) and 50ul of bacteria instilled directly to the 
trachea with the tongue pulled out to facilitate delivery of bacteria directly into the 
lungs. On average, about 2x105 cfu could be recovered from lung homogenates 
right after challenge, as determined by serial plating. Mice were monitored 
closely after i.t. infection and moribund mice were euthanized.  
Determination of the LD50 for i.t. Challenge: Naïve C57BL/6 mice were 
inoculated i.t. as described above with 5x103 cfu, 104 cfu, 5x104 cfu or 105 cfu of 
TIGR4 (n=6) in each group. Mice were monitored every 8 hours after the 
challenge and sacrificed when moribund. 67% of the mice survived 5x103 cfu 
challenge, and 50% survived 104 cfu and 5x104 cfu challenges. About 16% 
survived 105 cfu challenge.  
Blood Sample and Lung Homogenates: 10ul of tail vein blood collected in 90ul 
of anticoagulant (made by mixing 75ul of 1M Sodium Citrate, 50ul of 1M Citric 
Acid and 12.375mL of PBS pH7.4) was used for ELISAs. Lung homogenates 
were prepared by dissecting out all lobes, thoroughly rinsing with sterile PBS to 
remove blood on the surface of the organ and homogenized in 500ul of THY 
broth using a tissuemizer. 50ul of the homogenates were plated in serial dilutions 
to enumerate CFU in the lungs.  
Enzyme-Linked Immunosorbent Assay (ELISA) 
Nunc maxisorp® flat-bottom 96-well plates were coated overnight in 4oC with 106 
cfu/well of heat-killed whole pneumococci TIGR4 resuspended in 100ul of 
coating buffer (0.05M Na2CO3 pH9.0).  The next day, plates were washed three 
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times with wash buffer (0.05% PBS Tween) and blocked for 2 hours in blocking 
buffer (0.05% PBS Tween with 1%BSA). They were then washed three times 
before a 3-hr incubation with serum or lung homogenates at room temperature. 
Pneumococcal specific antibodies in the serum were detected by incubating with 
HRP-conjugated, goat anti-mouse IgM (1:5000) or IgG (1:10,000) antibodies for 
one hour at room temperature. After washing out the secondary antibodies, 
SureBlue Reserve TMB 1-Component Microwell Peroxidase Substrate system  
(Kirkegaard and Perry Laboratories) was added for 10 minutes before stopping 
with 1N NaOH solution. Each plate was read at OD450 using a spectromax plate 
reader. Control serum from a naïve mouse was always included on each ELISA 
plate and its OD450 value subtracted from other samples as “background”, unless 
otherwise noted on the graph.  
As described in Chapter 3, a kinetic ELISA with a reference hyperimmune serum 
was developed and used for antibody analyses for experiments later in this 
thesis. 
 
Data Analysis 
Statistical significance between two groups were determined using 
nonparametric, two-tailed, student t-test in GraphPad Prism. Survival analysis 
were performed by the log-rank (Mantel-Cox) test in GraphPad Prism.  
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Results 
B lymphocytes, but not T lymphocytes, are important to prevent lethal 
infection after intranasal inoculation. 
Serotype 4 strain of S. pneumoniae TIGR4 is a clinical bacteremia isolate 
that is highly invasive and virulent in mice [54]. In wild-type C57BL/6 mice, i.n. 
inoculation with a total of approximately 106 colony forming units (CFU) of TIGR4 
can establish nasopharyngeal colonization [42]. Immediately after inoculating a 
5µl suspension containing 5 x 105 CFU into each of the two nares of each mouse 
without anesthesia, an average of 105 pneumococci can be recovered from the 
nasal washes or nasal tissue homogenates (Figure S-1).  No bacteria could be 
detected in the blood or lungs of the inoculated mice (Figure S-1).  At 10 days 
after i.n. inoculation, similar numbers of bacteria can be recovered from the 
nasopharynx, although with more mouse-to-mouse variation.  The lungs and 
blood remained clear of bacteria (Figure S-1). This suggests that this method of 
i.n. inoculation results in pneumococcal colonization confined to the 
nasopharynx. Although transient and low-level aspiration of the bacteria into the 
lungs has been documented [55], the fact that 90% of wild-type mice did not 
suffer invasive pneumococcal disease and survived i.n. inoculation (Table 2-1) 
indicates that in majority of cases, either no bacteria became localized in the 
lung, or the host immune system was able to prevent lethal infection.  
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To determine whether B and T lymphocytes are required to control i.n. 
colonization by S. pneumoniae, we investigated the susceptibility of 
immunodeficient mice to i.n. inoculation (Table 2-1). Only 37% of Rag1-/- mice, 
which lack both B and T cells, survived i.n. inoculation (p = 0.002  compared to 
wild-type mice). Mature B cells contributed significantly, because µMT -/- and JH-/- 
mice, which lack these cells, were significantly (p = 0.031 and 0.023 respectively) 
more susceptible than wild-type, with survival rates of approximately 60%. The 
ability to secrete IgM is also important for full protection because only 63% of 
sIgM-/-  mice survived after i.n inoculation (p = 0.031). In contrast, T cell-deficient 
TCR βδ -/- mice uniformly survived i.n. inoculation. Our data suggest that IgM-
secreting B cells contribute to the prevention of lethal infection after i.n. 
inoculation of S. pneumoniae. 
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Pneumococcal-specific antibodies are generated upon single intranasal 
inoculation in wild-type and T cell-deficient mice.  
Given the increased susceptibility of the B cell-deficient mice to lethal 
infection following i.n. inoculation, we quantitated the level of pneumococcal-
specific antibodies in the serum following i.n. inoculation. To test this, blood 
samples were obtained at three and four weeks after single i.n. inoculation and 
antibody titers against heat-killed pneumococci measured by ELISA (Figure 2-1). 
As expected, B cell-deficient µMT-/- mice demonstrated no detectable responses 
in most cases (Figure 2-1,filled triangles). At both three and four weeks after 
inoculation,the anti-pneumococcal IgM titer of wild-type mice was higher than 
that of µMT-/- mice, but did not reach statistical significance.  In contrast, wild-type 
IgG levels were robust and significantly elevated compared to µMT-/- mice at both 
time points. Sera of sIgM-/- mice contained the predicted low levels of IgM, but 
displayed IgG titers only marginally lower than wild-type.  Finally, T cell-deficient 
mice generated IgG titers were not significantly elevated above titers of µMT-/- 
mice, but their IgM responses were well above these “background” levels at both 
three and four weeks and were comparable to those of wild-type mice (Figure 2-
1, bottom). The data indicate that the ability to generate a specific IgG response, 
but not the ability to generate an IgM response, is T cell-dependent.    
Notably, survival of mice following i.n. inoculation (Table 2-1) correlated 
with the anti-pneumococcal IgM but not IgG titers.  TCR βδ -/- mice, with near-wild 
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type levels of IgM, uniformly survived i.n. inoculation, despite levels of IgG 
significantly lower than wild-type (inverted triangles, p=0.002 at 3 weeks and 
0.005 at 4 weeks). Conversely, sIgM-/- mice were as susceptible after i.n. 
colonization as B cell-deficient mice, despite titers of IgG comparable to wild-
type.  
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Antibody responses and protection from subsequent intratracheal 
challenge are enhanced upon a second intranasal inoculation. 
 Multiple rounds of i.n. inoculation of S. pneumoniae can enhance 
protective responses against subsequent nasopharyngeal colonization [29, 30]. 
To test whether a second i.n. inoculation leads to better a humoral immune 
response, we measured anti-pneumococcal antibodies in the sera of mice that 
were i.n. inoculated either once or twice with one week interval. One week after 
the final inoculation, IgM levels between the two groups remained similar (Figure 
2-2 A, left panel). However, compared to single i.n. inoculation, mice that were 
i.n. inoculated twice responded with significantly (p<0.001) higher serum IgG 
levels (Figure 2-2 A, right panel).  
 We next tested whether i.n. inoculated mice were protected from 
subsequent i.t. challenge. Three weeks after completing i.n. inoculation, mice 
were challenged intratracheally = with 5x105 CFU, i.e., 50 times the LD50 of S.p. 
TIGR4 (see methods) This challenge resulted in death of naïve mice within 72 
hours (Figure 2-2 B, filled circles). Fifty percent of mice that were i.n. inoculated 
only once survived this challenge (open circles), a percentage that was not 
statistically different from the survival of naïve counterparts. A second i.n. 
inoculation increase the percent survival to 78% after a challenge of 5x105 CFU 
(Figure 2-2 B, right panel). Twice inoculate mice exhibited a 50% survival rate 
after a higher i.t. challenge dose of 2x107 CFU (~2,000x LD50; Figure 2-2C).  
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 The better protection from i.t. challenge after two i.n. inoculations 
correlated with higher antibody titers in the serum and lungs after challenge. 
Forty-eight hours after i.t. challenge, serum and lung homogenates samples were 
tested for antibodies against heat-killed pneumococci. Consistent with enhanced 
IgG responses after second i.n. inoculation, we found a higher (p=0.004) level of 
IgG in the lung homogenates of mice that were twice inoculated. Interestingly, 
serum IgG levels were similar in mice that were inoculated once or twice.  
Therefore, it was clear that multiple rounds of i.n. inoculation with TIGR4 
strain can increase serum pneumococcal antibody levels after i.n. incoculation 
and mucosal IgG responses after lung challenge. The more robust antibody 
response correlated with enhanced survival from i.t. challenge.  
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Intranasal colonization of BALB/c mice elicits better protection against 
subsequent intratracheal challenge.  
 Susceptibility of mice to pneumococcal infection varies with mouse strain. 
In particular, the ability of BALB/c mice to elicit better macrophage acitivity and 
neutrophil recruitment in the lungs than C57BL/6 mice in response to S. 
pneumoniae infection has been documented [32]. Therefore, we evaluated how 
i.n. colonized BALB/c mice survived i.t. challenge. First, similar to C57BL/6 mice, 
two i.n. inoculations conferred significant protection upon i.t. challenge with 5x105 
CFU of S.p. TIGR4 (100% survival, Figure 2-3 A) Remarkably, twice inoculated 
mice were also completely protected when a higher dose of 2x107 CFU was used 
(Figure 2-3 B), in contrast to the significantly lower survival rate of 50% for twice-
inoculated C57BL/6 mice (Figure 2-2 B). Our data suggests that host factors 
influence the kinetics and quality of protective responses elicited by i.n. 
inoculation and that BALB/c mice are more proficient at mounting a protective 
response after i.n. inoculation than C57BL/6 mice.  
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Three rounds of intra-nasal inoculation in C57BL/6 mice result in 
significant protection against intra-tracheal and intra-peritoneal S. 
pneumoniae challenge.  
C57BL/6 mice, in contrast to BALB/c mice, did not exhibit complete 
protection from a high dose i.t. challenge after two rounds of i.n. exposure 
(Figure 2-2). Therefore, we tested if a third round of i.n. inoculation improved 
antibody responses and survival rates (Figure 2-4). C57BL/6 mice were i.n. 
inoculated three times at weekly intervals. One week after last inoculation, mice 
were treated i.p. with 1mg of Rifampicin for two consecutive days to ensure that 
infection was cleared.  
We challenged the mice with 2x106 CFU (~200 LD50), a dose that in all 
naïve mice led to high-level bacteremia within 24 hours (data not shown) and 
moribund animals by 84 hours (open triangles). In contrast, eight of the ten mice 
that had been colonized i.n. three times survived the i.t. challenge (filled circles, p 
= 0.002). In order to evaluate protection from bacterial growth in the lungs, we i.t. 
challenged previously i.n. colonized mice with 2x105 CFU (~20 LD50) of S. 
pneumoniae TIGR4, a dose that allowed for extended survival of both the 
experimental and control groups. Lung homogenates of naïve mice contained 
approximately 105 pneumococci/200mg at 48 and 65 hours after challenge, 
(open triangles). In contrast, the bacterial loads in the lungs of i.n. colonized mice 
(filled circles) were ~15-fold lower (p <0.04) at both time points. Our results 
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clearly demonstrated that protection of mice from i.t. challenge after three rounds 
of i.n. inoculation was associated with the ability to controll bacterial burden in the 
lung. 
Upon i.t. challenge with 2x106 CFU (~200 LD50), naïve and two of the ten 
mice that had previously been inoculated three times suffered overwhelming 
bacteremia and died after i.t. challenge (Figure. 2-4A and Figure S-2 A), 
suggesting a progression of lung infection into lethal sepsis and raising the 
possibility that the eight previously colonized survivors were protected from 
systemic as well as pulmonary infection.  Indeed, we found that i.n. colonized 
mice are able to resist bacteremia after subsequent i.t. challenge with 2x105 CFU 
(~20 LD50) of S. pneumoniae TIGR4 (Figure 2-4C). At 48 and 65 hours post 
challenge, i.n. colonized mice were clear of bacteria in their blood samples (filled 
circles) while naïve mice suffered bacteremia approaching 106/ml (open 
triangles, p <0.01 at 48 hours and <0.03 at 65 hours).  
To directly determine if the three times-i.n. colonized mice acquired 
immunity to systemic challenge, these mice, or naïve controls, were challenged 
by i.p. inoculation with 100 CFU of S. pneumoniae strain TIGR 4.  Whereas naïve 
mice suffered high-level bacteremia and uniformly died within 48 hours, 
previously colonized mice displayed a 100% survival rate, with only one of five 
mice demonstrating a transient (low-level) bacteremia at one time point (Figure 
2-4D, left panel, p = 0.005, and Figure S-2 B). We conclude that three doses of 
i.n. inoculation triggers in C57/Bl6 mice an immune response that protects from 
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both pulmonary and systemic infection. For simplicity, we herein refer to mice 
receiving the three dose protocol as “3x i.n. colonized mice”. 
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Intranasal colonization induces varying degrees of protection from 
intratracheal challenge with other serotypes.  
We next asked if i.n. colonization-induced protection in the lungs can be 
achieved when challenged with a heterologous strain. To test this, mice that 
were i.n. colonized with serotype 4 strain TIGR4 were challenged i.t. with 107 
CFU of serotype 19A strain Hungary, which is incapable of causing lethal 
infection in C57/Bl6 mice (data not shown; Figure. 2-5A). By 48 hours after 
challenge, the average bacterial burden in the lungs of i.n. colonized mice (filled 
circles) was about 30-fold lower than naïve counterparts (open triangles) 
although the variation among mice was too large to reach statistical significance.  
At 72 hours, the difference in bacterial load was still evident, with i.n. colonized 
mice having 15-fold lower CFU in the lungs than naïve mice (p=0.048). These 
results suggest that post-colonization protection against lung infection may be 
serotype-independent.  
We further investigated serotype-independent protection with strains 
capable of causing lethal infection. As expected, i.n. colonization with serotype 4 
strain TIGR4 protected against subsequent challenge with the same strain 
(Figure 2-5B, “serotype 4 colonized” filled circles). However, mice  i.n. colonized 
with serotype 2 strain D39 (Figure 2-5B “serotype 2 colonized”, filled squares) 
not protected from subsequent challenge with TIGR4 (p<0.001) Similarly, after 
i.n. colonization with a serotype 14 strain, i.t. challenge with serotype 4 resulted 
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in protection in only 40% of the mice (Figure 2-5C “TIGR4 i.n.”, filled squares). 
This phenotype was intermediate between naïve mice  (open triangles) and 
mice colonized with the homologous strain (filled circles), with no significant 
difference from either of the control groups. Taken together, our data suggests 
that the degree of serotype-independent protection is a function of the particular 
strains tested and that i.n. colonization by a single serotype is unlikely to protect 
against all pneumococcal serotypes. 
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Discussion 
  Intranasal carriage by S. pneumoniae can prime the immune system to 
protect against subsequent invasive infection [6, 10]. Indeed, we have shown 
here that certain components of adaptive immunity are required to control 
nasopharyngeal infection, because immunodeficient hosts such as Rag1-/-, JH-/- 
and µMT -/- and sIgM-/- mice suffered lethal infection after i.n. inoculation. The fact 
that T cell-deficiency did not compromise survival after i.n. inoculation suggests 
that T-independent B lymphocytes play an important role in generating the 
protective response. The IgM levels of the TCR βδ-/- mice appeared to be 
elevated relative to the “background” levels of the µMT mice, but the sample 
sizes were small and statistical significance was not achieved. Nevertheless, 
these levels of IgM may be important because TCR βδ-/- mice survived intranasal 
inoculation at the wildtype level despite decreased IgG responses. Similarly, 
mice deficient in secreted IgM have titers of pneumococcal specific IgG that are 
comparable to those of TCR βδ-/- mice and only marginally lower than wild-type 
mice. Despite higher IgG levels, they were significantly more susceptible after i.n. 
inoculation, suggesting that IgM is more important than IgG in controlling i.n. 
colonization. Natural anti-capsular IgM antibodies made by B1a cells and anti-
phosphorylcholine antibodies from unimmunized mice are protective against 
systemic pneumococcal diseases [1, 13]. In addition, natural antibodies along 
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with complement have been shown to mediate neutralization in the absence of 
prior immunity in mucosal viral infections [15, 56]. Therefore, it is possible that in 
the event of low-level escape of colonizing S. pneumonaie from the nasopharynx 
into the lung or bloodstream, natural antibodies and complement are sufficient to 
prevent lethal diseases.  
 The adaptive immune responses elicited by nasopharyngeal colonization 
are capable of providing protection against subsequent invasive infections. We 
have shown here that both C57BL/6 and BALB/c mice were protected from 
otherwise lethal i.t. challenge as a consequence of prior i.n inoculation. The 
levels of protection depended upon both the number of intranasal exposure, dose 
and serotype of the challenge and the particular mouse strain.  
BALB/c mice demonstrated an enhanced protective response, an 
observation that is perhaps not surprising given previous studies showing certain 
genetic factors in BALB/c mice that make them less susceptible to pneumococcal 
infections. Compared to C57Bl/6 mice, after intranasal challenge, BALB/c mice 
had 1) longer survival time, better control of bacterial loads in the lungs and 
fewer cases of bacteremia; 2) more intense and rapid neutrophil influx into the 
lungs; and 3) better phagocytic activity and oxidative burst of macrophages after 
i.t. challenge [32]. In addition, BALB/c mice are colonized at higher densities and 
for a longer period of time compared to C57BL/6 mice in experimental carriage 
models [57], suggesting that BALB/c mice may experience a greater antigenic 
load during colonization, leading to more robust immune responses. Studying 
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protective responses in host strains such as C57BL/6 with intermediate 
susceptibility may be more relevant for protecting at-risk individuals in the human 
population. Moreover, various genetic knockout mice available on the C57BL/6 
background are important tools to investigate involvement of specific lymphocyte 
subsets and antibody isotypes. 
 S. pneumoniae (TIGR4) is a clinical isolate that expresses a capsular 
serotype incuded in current polysaccharide vaccines. In mouse models of 
intranasal colonization, three intranasal exposures at weekly intervals by this 
strain was protective against nasopharyngeal re-colonization [42, 43].  Our 
results here indicated that a second round of intranasal inoculation by TIGR4 
enhanced anti-pneumococcal antibody responses. Nevertheless, protection from 
i.t. challenge with a high dose (~2,000x LD50) challenge required a third round of 
intranasal exposure. Three rounds of i.n. colonization was found to also offer 
protection against intraperitoneal challenge and served as the basis for our 
experimental design in subsequent studies. We modeled intranasal colonization 
in subsequent studies by three rounds of intranasal inoculations at weekly 
intervals and rifampicin treatment at 1 week after last inoculation. This collective 
procedure will be referred to as “i.n. colonization” hereafter in this thesis.  
 Overwhelming S. pneumonia burden in the lungs can lead to bloodstream 
infections. Indeed, we found here that when S. pneumoniae is directly inoculated 
into the trachea, it is able to translocation into the bloodstream within 48 hours. 
Prior nasopharyngeal colonization diminished bacterial burdens both in the lungs 
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and in the bloodstream. It is possible that both local and systemic responses are 
required to prevent death upon i.t. challenge.  
 Finally, we have presented evidence that i.n. colonization by single 
serotype may not be sufficient to protect against all strains of S. pneumoniae. In 
humans, individuals are colonized by multiple strains (simultaneously or 
sequentially) in early childhood [7]. In addition, studies have suggested that an 
anticapsular response may not be the primary mechanism of the putative 
resistance to colonization and that antibodies directed against pneumococcal 
proteins, elicited upon carriage in human, may contribute to this apparent 
protection [6, 17]. It is possible that in humans, a combination of anticapsular and 
anti-protein antibodies resulting from multiple exposures with different serotypes 
would allow for both serotype-dependent and independent protection in middle-
aged individuals. It would be interesting to identify the anti-pneumococcal 
antibodies that are likely required for colonization-induced protection as well as 
the subsets of lymphocytes that are involved in this protective response.   
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Chapter III. 
PROTECTIVE RESPONSES FOLLOWING INTRANASAL COLONIZATION WITH 
STREPTOCOCCUS PNEUMONIAE ARE B-CELL MEDIATED AND DO NOT REQUIRE CD4+ T 
CELLS AT THE TIME OF INTRATRACHEAL CHALLENGE. 
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Abstract 
 In the previous chapter, we showed that nasopharyngeal colonization of 
C57/Bl6 mice by S. pneumoniae elicited pathogen-specific antibodies and 
protected against an otherwise lethal intratracheal (i.t.) challenge. Here, we 
investigate aspects of the immune system that are important for protective 
responses. We found that protection against i.t. challenge required B 
lymphocytes, and transfer of immune sera from i.n. colonized mice or a 
monoclonal antibody against the conserved surface antigen phosphorylcholine 
conferred protection to naïve mice. The ability of mice to generate IgA, the 
isotype most closely associated with mucosal defense, contributed to but was not 
absolutely required for protection following nasopharyngeal colonization. Analysis 
of TCRβδ-/- mice indicated that T cells also contributed to protection, but 
depletion of CD4+ cells at the time of i.t. challenge did not compromise survival, 
suggesting that the critical responses during secondary infection does not require 
CD4 T cells. Protection against i.t. challenge lasted for at least ten weeks after 
i.n. colonization.  B1b cells, a subset of B1 lymphocytes in the peritoneal cavity 
can function as memory cells that can differentiate into IgM-secreting plasma 
cells in a CD4 T cell-independent manner, but transfer of peritoneal cells from 
mice previously colonized in the nasopharynx was not sufficient to confer on Rag-
/- mice protection against i.t. challenge following i.n. colonization. In contrast to 
memory B cells, long lived antibody secreting cells are resistant to irradiation. We 
found that sub-lethal irradiation of mice after i.n colonization did not significantly 
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diminish survival after i.t. challenge, consistent with the suggestion that long 
lasting colonization-induced protection is mediated by anti-pneumococcal 
antibody secreted by long lived plasma cells.  
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Introduction 
Streptococcus pneumoniae is a common inhabitant of the nasopharynx, 
with carriage rates approaching 40% in adults and 100% in children of the 
developing countries [3]. While intranasal carriage is typically asymptomatic and 
self-limiting, it can also progress to invasive disease [10], the most common of 
which is lung infection. In fact, S. pneumoniae is the most frequent cause of 
community-acquired bacterial pneumonia in the U.S. An antiphagocytic 
polysaccharide capsule permits high-level growth in the bloodstream, and lung 
infection can lead to septicemia and meningitis. Thus, invasive pneumococcal 
disease is responsible for over 1.6 million deaths per year worldwide, especially 
in infants, the elderly and immunocompromised individuals [7].  
The observation that S. pneumoniae can cause invasive infections but is a 
common component of the nasopharyngeal flora raises the possibility that 
intranasal colonization elicits an immune response that prevents systemic 
disease in most individuals. The rate of nasopharyngeal colonization declines 
with age, consistent with the hypothesis that successive episodes of the S. 
pneumoniae colonization may induce protective mucosal immune responses [6]. 
Similarly, rates of invasive pneumococcal diseases are highest in young children 
and decreases markedly starting the third year of life, corresponding to the 
maturation of the adaptive immune system. Adaptive immune responses to 
natural colonization may contribute to this age-specific decline in pneumococcal 
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infection, but the nature of this response is poorly understood [6]. The incidence 
then rises in persons over the age of 65, which is thought to be due to a 
decrease in immune responsiveness that occurs with aging [11, 58, 59] 
It is well established that systemic immunization with pneumococcus (or 
components of the bacterium) results in protection from invasive disease. 
Intravenous or intraperitoneal immunization with heat-killed pneumococci 
protects rabbits and mice against lethal pneumococcal sepsis, and protection 
correlates with robust antibody responses [34, 35]. Several constituents of the 
bacterium appear to contribute to protection.   
The best-studied component that elicits a protective antibody response is 
the S. pneumonia antiphagocytic polysaccharide capsule, a T-independent 
antigen that is the basis for current vaccines. In mice, at least two B lymphocyte 
populations, including peritoneal B1b lymphocytes and long-lived plasma cells 
that reside in the bone marrow, appear to be capable of contributing to protection 
following polysaccharide immunization. B1b cells are a class of B1 lymphocytes 
that can provide T-independent, long term protection against Borrelia hermsii and 
S. pneumoniae [1, 22, 60]. Peritoneal B1b cells in mice produce anti-
pneumococcal antibodies and are sufficient to provide long-term protection 
against systemic pneumococcal challenge [1]. In addition, long-lived plasma cells 
that reside primarily in the bone marrow can be generated in a T-independent 
manner upon immunization. In mice, after immunization with pneumococcal 
polysaccharides and a CpG adjuvant, radio-resistant, long-lived bone marrow 
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plasma cells are sufficient to protect mice against systemic pneumococcal 
challenge [2].  
A second antigen that contributes to protection is phosophorylcholine 
(PC), a cell wall component of S. pneumoniae. Naive mouse serum contains high 
levels of naturally-occurring antibodies against PC. Such anti-PC antibodies are 
considered a constituent of “natural antibody”, a response in mice mediated 
primarily by the B1a subclass of lymphocytes present in the peritoneum [1]. Anti-
PC monoclonal antibodies that bear the T15 idiotype are protective against 
intravenous challenge with S. pneumoniae, and this response is mediated by T-
independent B1 cells [13, 20, 61, 62]. PC is a common, antigenically constant 
component of all pneumococci, and is thus an attractive antigen for inducing 
serotype-independent protective responses.   
Potential serotype-independent protective antibody responses can also be 
achieved by T-dependent responses against specific S. pneumoniae proteins. 
Immunization with various pneumococcal surface proteins such as 
pneumococcal surface protein A (PspA) or C (PspC) protect against lethal 
infection in mice [27, 36] and passive transfer of immune sera against PspA or 
PspC is protective [37], suggesting that antibodies against these protein antigens 
can provide systemic protection.  
Nasopharyngeal colonization also results in an immune response that 
limits subsequent re-colonization.  Whereas it is clear that antibodies play the 
central role in protection against systemic disease following immunization with S. 
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pneumoniae or its components, depending on the experimental system either T 
or both T and B cells have been implicated in a local protective response in the 
nasopharynx. Secretory IgA is thought to play a critical role in the protection of 
mucosal surfaces from infection, but following intranasal colonization with live, 
wild-type pneumococci or purified pneumococcal proteins, mice are protected 
from re-colonization in an antibody-independent, IL17-producing CD4+ T cells-
dependent manner [34, 40, 42, 43, 45]. On the other hand, after colonization with 
attenuated S. pneumoniae, reduction in intranasal carriage following high-volume 
intranasal challenge, which results in the aspiration of bacteria into the lungs and 
their subsequent translocation into the bloodstream, requires both antibodies and 
CD4+ T cells [30].  
Finally, several studies suggest that nasopharyngeal colonization also 
results in immune responses that can provide protection from pulmonary 
infection. Intranasal colonization with live-attenuated strain of S. pneumoniae 
protects mice against systemic disease following a high-volume intranasal 
challenge [30]. This protection from development of lung infection into lethal 
sepsis is compromised in either antibody-deficient or MHCII-/- mice, suggesting 
that both antibodies and CD4+ T cells are essential. More recently, in a study 
using outbred mice, prior colonization by an attenuated S. pneumoniae strain 
resulted in protection against subsequent systemic infection following aspiration 
of nasopharyngeally inoculated pneumococci into the lungs. Although the use of 
outbred mice precluded a straightforward genetic test using knockout mice of the 
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role for antibodies or CD4+ T cells, this protection correlated with increased levels 
of IL17A and CD4+ T cells in the lungs as well as a vigorous antibody response 
(Richards, Ferreira et al. 2010) In both studies, significant titers of 
pneumococcal-specific mucosal IgA were detected, but the significance of this 
response in protection against invasive mucosal infection was not tested.  
The immune response elicited by nasopharyngeal colonization by 
attenuated strains suggests that colonization by wild-type pneumococci may also 
induce protection against pulmonary infection in mice, consistent with the 
hypothesis that the relatively infrequent incidence of pneumococcal pneumonia 
and systemic disease may be in part a result of a protective immune response 
triggered by the high frequency of asymptomatic nasopharyngeal colonization. In 
the previous chapter, evidence was presented that a humoral immune response 
was required for C57BL/6 mice to survive i.n. inoculation of wild-type 
pneumococci, suggesting that colonization of this site may elicit an adaptive 
immune response.  In addition, we found that a protocol of multiple i.n. 
inoculations resulted in protection from pulmonary and bloodstream infection 
after intratracheal (i.t.) or intraperitoneal (i.p.) challenge. In the current study, we 
took advantage of availability of genetically-engineered C57/Bl6 mice to 
investigate specific requirements of the response. Our results highlight the 
importance of B cells and antibodies for colonization-induced protection from 
lung infection, and suggested that long-lived plasma cells, as well as T cells, 
contribute significantly to protective responses.  
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Materials and Methods 
Mice 
 In addition to the mice described in materials and methods section of chapter II, 
IgA-/- mice were described in [63], backcrossed to C57BL/6 and deposited to 
University of Missouri Mutant Mouse Regional Resource Center by Dr. Dennis 
W. Metzger at the Albany Medical College. JH-/- mice on C57BL/6 background 
were originally obtained from Dr. Klaus Rajewsky at Immune Disease Institute of 
Harvard Medical School. CD93-/- mice were from Dr. Andrea Tenner at University 
of California Irvine (originally from Dr. Marina Botto of Rheumatology Section at 
the Imperial College in London, UK). At UMMS, CD93-/- , IgA-/- and JH-/- mice were 
obtained from the colony of Dr. Rachel Gerstein (UMMS) and bred and 
maintained in our colony. CD4-/- mice on the BALB/c background were obtained 
from the colony of Dr. Susan Swain (UMMS).  
Bacteria 
The bacteria were grown overnight on tryptic soy agar plates supplemented with 
5% sheep blood (Northeast Labs; P1100). The colonies were then washed off 
the plates with 1mL of Todd Hewitt Yeast Broth (THY) and grown in THY+5ul/mL 
of oxyrase® (Fisher catalog # 502005299) in 37oC 5% CO2. Bacteria were 
harvested at OD600=0.8 or ~5.0x108 CFU/ml (late log phase). Serotype was 
confirmed by quelleng  reaction and aliquots were prepared by combining the 
culture with equal volume of 50% glycerol in THY broth (final concentration = 
~2.5x108/mL in 25% glycerol). The aliquots were frozen at 80o C until further use. 
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Each frozen tube was thawed and the bacteria were washed 3 times with 1x PBS 
and resuspended in 250ul of 1xPBS (=107CFU/10ul inoculum) for i.n. inoculation 
or diluted in 5mL of 1xPBS to ~4x107/mL (=2x106/50ul inoculum) for i.t. 
challenge. The size of each inoculum was confirmed by plating serial dilutions. 
Serotype 4 strain TIGR 4 strain used for all experiments in this chapter was a 
kind gift from Dr. Andrew Camilli at Tufts University Sackler School of Biomedical 
Sciences.  
 
Animal Infections 
Intranasal Inoculation : Mice were restrained without anesthesia and given 10ul 
(107 cfu) of bacteria equally distributed between the nostrils with a pipette. Doses 
were confirmed by plating serial dilutions of the inocula. To establish 
nasopharyngeal colonization, i.n. inoculations were repeated three times at 
weekly intervals and one week after the last inoculation, mice were treated with 
1mg of Rifampacin intraperitoneally for 2 consecutive days.  
Intratracheal Challenge (i.t.):  Lethal lung infections were given by i.t. 
inoculation at three weeks after the last i.n. inoculation. Mice were lightly 
anesthetized with Isoflurane (USP) and 50ul of bacteria instilled directly to the 
trachea with the tongue pulled out to facilitate delivery of bacteria directly into the 
lungs. On average, about 2x105 cfu could be recovered from lung homogenates 
right after challenge, as determined by serial plating. Mice were monitored 
closely after i.t. infection and moribund mice were euthanized.  
61
Intraperitoneal Immunization (i.p immunized): 107CFU of TIGR4 were heat-
killed at 65oC for two hours and suspended in 250ul of 1xPBS for i.p. injection 
into each mice. Mice were i.p. immunized with heat-killed TIGR4 twice with two 
weeks apart.  
Pneumovax Immunization: Mice were immunized by i.p. injection with 50ul of 
human adult polysaccharide vaccine (pneumovax). This preparation contains 
2.5ug of each of the 23 polysaccharides in isotonic solution. i.t. challenges were 
performed two weeks after immunization.    
Blood Sample and Lung Homogenates: 10ul of tail vein blood collected in 90ul 
of anticoagulant (made by mixing 75ul of 1M Sodium Citrate, 50ul of 1M Citric 
Acid and 12.375mL of PBS pH7.4) was used for ELISAs. Lung homogenates 
were prepared by dissecting out all lobes, thoroughly rinsing with sterile PBS to 
remove blood on the surface of the organ and homogenized in 500ul of THY 
broth using a tissuemizer. 50ul of the homogenates were plated in serial dilutions 
to enumerate CFU in the lungs.  
Lung Washes: Mice were euthanized by CO2 asphyxiation and the trachea 
exposed. Trachea was nicked with a small sharp needle, and intramedic 
polyethylene Tubing (PE60, Becton Dickinson catalog number 427415) was 
inserted about 0.5cm down towards the lung. Once inserted, a knot was tied 
around top of the trachea with a regular thread to prevent leakage.1.5mL of 
sterile 1XPBS was pushed in and out of the lungs three times through a needle 
attached to the end of the tubing.  
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Serum Transfer 
Three weeks after i.n. colonization, mice were sacrificed and blood collected by 
cardiac puncture and incubated at 37oC for one hour. The blood tubes were then 
spun down for 8 minutes at 0.8rcf in the microfuge. The clear serum portion was 
carefully collected and pooled. Mice were given 400ul of pooled sera by i.p. 
injection and challenged 24 hours later.   
Anti-PC mAb treatment 
Anti-PC mAb (IgG) was a kind gift from Dr. Ann Rothstein (UMMS) and originally 
made from clone HPCG11, which has been previously described in [64]. Anti-PC 
mAb (IgA) made from clone TEPC 15 was purchased from Sigma (Catalog 
Number M1421). Antibodies were dialyzed against sterile 1xPBS before use. 
Mice were treated with 50ul of anti-PC mAb (IgA) or 50ug of anti-PC mAb (IgG) 
by i.p. injection 24 hours prior to challenge.  
CD4-depletion  
 At -2, -1 and +1 day of challenge, mice were treated with monoclonal 
antibodies against CD4 (clone GK1.5) (obtained from Dr. Rachel Gerstein at 
UMMS). By the time of challenge, depletion of CD4+ cells was confirmed by 
FACs staining of peripheral lympchocytes. After red-cell lysis, peripheral blood 
lymphocytes were washed and resuspended in staining medium (deficient RPMI 
1640, Hepes: 10mM, Final pH = 7.2 supplemented with 3% new calf serum, 
0.02% Sodium Azide). Fc receptors were blocked with 2.4G2 antibody (Becton 
Dickinson, Franklin Lakes, NJ) at 1µg per 106 cells, followed by incubation of 
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10µl of cells with antibodies in a microtiter plate. B220-FITC, CD4-PE and 
CD8cy5-PE antibodies were used for staining and analysis at the UMMS FACs 
core facility. The data was analyzed using Flowjo software.  
Sublethal Irradiation 
Two days prior to irradiation, mice received a mixture of antibiotics (neomycin 
sulfate and polymyxin sulfate; 0.5mg/mL of each antibiotic) in water, which was 
replenished every week until three days before challenge. Mice received total, 
wholebody irradiation at a sublethal dose 6.0 Gy (600 rad), γ ray source) at three 
weeks after i.n. colonization. Challenges were performed at two weeks after 
irradiation.   
Adoptive transfer of peritoneal cells  
RAG1-/- mice were reconstituted with un-fractionated peritoneal cavity cells from 
naïve C57BL/6 (WT) mice as previously described (Marty-roix; UMMS thesis and 
[22]). Briefly, peritoneal cavity cells were collected, pooled and washed 3 times in 
sterile 1x PBS. The cells were then suspended in 250ul and given to the 
recipients by intraperitoneal injection. Un-fractionated peritoneal cells were 
reconstituted at a ratio of 2 donor mice to 1 recipient mouse (~2.5 million cells 
per recipient).  
 
Enzyme-Linked Immunosorbent Assay (ELISA) 
Nunc maxisorp® flat-bottom 96-well plates were coated overnight in 4oC with 106 
cfu/well of heat-killed whole pneumococci TIGR4, 1ug/well of phosphorylcholine 
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(PC-BSA; Biosearch Technologies PC1011H-10) or polysaccharide-4 (PPS; 
ATCC) in 100ul of coating buffer (0.05M Na2CO3 pH9.0). The next day, plates 
were washed three times with wash buffer (0.05% PBS Tween) and blocked for 2 
hours in blocking buffer (0.05% PBS Tween with 1%BSA). They were then 
washed three times before a 3-hr incubation with serum or lung homogenates at 
room temperature. Pneumococcal specific antibodies in the serum were detected 
by incubating with HRP-conjugated, goat anti-mouse IgM, or IgG or IgA 
(1:10,000) antibodies for one hour at room temperature. After washing out the 
secondary antibodies, 100ul SureBlue Reserve TMB 2-Component Microwell 
Peroxidase Substrate system  (Kirkegaard and Perry Laboratories) was added to 
each well and each plate was read at OD650 using a Spectromax 250 plate 
reader. Kinetic ELISA was used and readings were taken every 30 seconds for 
12 or 15 minutes.  
Sera used in this thesis were not pre-absorbed with pneumococcal cell 
wall polysaccharides CWPS before using for ELISA assays. We are currently 
working to determine if anti-PPS antibody responses we observed are influenced 
by pre-incubation of immune sera with purified CWPS.  
Calculation of antibody units: In order to standardize the experiments, a 
positive control sample was prepared. Wild-type C57BL/6 mice were i.n. 
inoculated with TIGR4 at week 0 and 1, i.p. immunized with heat-killed TIGR4 at 
week 3 and i.t. challenged at week 5. Sera from these mice were collected, 
pooled and frozen in aliquots at -80C and included as “hyperimmune” standards 
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in each plate.  
Determination of Antibody Units using a hyperimmune standard 
Serial dilutions of 1ul of the hyperimmune standard or sample sera were 
used in kinetic ELISA assays to determine Vmax values that are in a linear 
range. For the standard and each sample, the highest Vmax in the range was 
used to calculate antibody units. We define the Vmax of the hyperimmune as 100 
antibody units. In other words, to obtain the same Vmax value as the 
hyperimmune standard, a sample must contain 100 antibody units in 1ul of 
mouse serum.  
A hyperimmune standard was run on each ELISA plate and Vmax 
(hyperimmune) determined for each antigen and antibody isotype.  Using the 
above definition, antibody units of the samples against the same antigen were 
calculated and standardized.   
 
Determination of antibodies present in the hyperimmune standard 
In order to estimate the amount of antibodies present in the hyperimmune 
standard, the following purified antibodies or a mouse reference serum with 
predetermined concentration of antibodies were used.  
 
Anti-PC IgA (Sigma M1421) 
 Plates were coated with purified PC-BSA (PC-1011H-10 Biosearch 
Technologies) and probed with anti-PC IgA or hyperimmune standard. 
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We define 100 antibody units as the Vmax generated by 1 ul of 
hyperimmune serum assayed for a particular antibody, in this case anti-PC IgA. 
Based on the Vmax obtained with purified anti-PC IgA, 1 ug of this preparation 
corresponds to 1100 antibody units.  Therefore, 100 antibody units is estimated 
to represent 90 ng of anti-PC IgA antibody/ul of mouse serum. 
 
Anti-Mouse IgA  
 Plates were coated with affinity purified Mouse IgG Coating Antibody 
(A90-103A) and probed with a mouse reference serum (Bethyl RS10-101) 
We define 100 antibody units as the Vmax generated by 1 ul of 
hyperimmune serum assayed for a particular antibody, in this case anti-mouse 
IgA. Based on the Vmax obtained with the mouse reference serum, 0.5 ng of 
anti-mouse IgA in this preparation corresponds to 0.18 antibody units.  Therefore, 
100 antibody units is estimated to represent 278 ng of anti-mouse IgA antibody/ul 
of mouse serum. 
 
Anti-Mouse IgG  
 Plates were coated with affinity purified Mouse IgG Coating Antibody 
(A90-131A) and probed with a mouse reference serum (Bethyl RS10-101) 
We define 100 antibody units as the Vmax generated by 1 ul of 
hyperimmune serum assayed for a particular antibody, in this case anti-mouse 
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IgG. Based on the Vmax obtained with the mouse reference serum, 0.5 ng of 
anti-mouse IgG in this preparation corresponds to 0.12 antibody units.  
Therefore, 100 antibody units is estimated to represent 417 ng of anti-mouse IgA 
antibody/ul of mouse serum. 
 
Therefore, 100 antibody units in this thesis contain approximately 
90 ng of anti-PC IgA antibody/ul of mouse serum.  
278 ng of anti-mouse IgA antibody/ul of mouse serum 
417 ng of anti-mouse IgG antibody/ul of mouse serum 
 
Enzyme-linked immunosorbent spot (ELISPOT) 
 
MultiscreenHTS® filter 96-well plates (MSHAN4550) were coated overnight in 4oC 
with 106 cfu/well of heat-killed whole pneumococci TIGR4, 1ug/well of 
phosphorylcholine (PC-BSA; Biosearch Technologies PC1011H-10) or 
polysaccharide-4 (PPS; ATCC) in 100ul of coating buffer (0.05M Na2CO3 pH9.0).  
The next day, plates were washed three times with wash buffer (0.05% PBS 
Tween) and blocked for 1 hours in RPMI complete supplemented with 10% Fetal 
Bovine Serum. Freshly-harvested mouse cells were added to wells (in 
duplicates) at 106/well, 2x105/well, or 4x104/well and incubated at 370C with 5% 
CO2 for 6 hours. The cells were then washed out (subsequent washes are 8 
times with water) and blocked overnight at 4C with 100ul/well of 1 x PBS+ 
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1%FBS. The next morning, plates were washed and 50ul of biotin-conjugated 
anti-mouse IgG, IgM or IgA was added in dilution 1:2000 (in 1% FBS in PBS) and 
incubated for 3 hours at room temperature. Unbound antibodies were then 
washed out and 50ul of streptavidin-AP secondary antibody was added at 1:3000 
(in 1% FBS in PBS) for one hour at room temperature. The plates were then 
washed again and developed by adding SIGMAFAST™ BCIP®/NBT to 10ml of 
water per 2 plates (50ul/well). The plates were closely monitored and the reaction 
stopped by extensive washing immediately after the darkest spots became 
visible. Plates were left overnight covered with aluminum foil for drying. Spots 
were scanned and counted using CTL Immunospot analyzer ® (Cellular 
Technology).  
Data Analysis 
Statistical significance between two groups were determined using 
nonparametric, two-tailed, student t-test in GraphPad Prism. Survival analysis 
were performed by the log-rank (Mantel-Cox) test in GraphPad Prism.  
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Results  
A humoral immune response is essential for colonization-induced 
protection.  
 Our results presented in the last chapter suggest that B cells are required 
to prevent lethal infection after i.n. inoculation of serotype 4 S. pneumoniae strain 
TIGR4. Therefore, we measured pneumococcal-specific antibodies in i.n. 
colonized mice three weeks after i.n. colonization, at a time of demonstrable 
immunity. Antibody titers were determined from serum, lung homogenates and 
lung (Figure 3-1). Heat-killed whole bacteria (“TIGR4”) were used as antigens for 
the ELISA assay along with two important pneumococcal components: purified 
pneumococcal polysaccharides (PPS) and phosphorylcholine (PC). Previous 
studies have shown that i.p. immunization with heat-killed pneumococci elicit 
robust serum antibody responses that protect against lethal systemic infection 
[35], and samples from heat-killed i.p. immunized mice were included as a 
positive control where indicated.  
At the time of challenge, significant titers of IgG antibodies against all 
tested antigens were detected in the sera of i.n. colonized mice (Fig 3-1A). Lung 
homogenates also had similarly high IgG titers (Figure 3-1B top panel). IgA is 
expected to be generated during nasopharyngeal infection by mucosal 
pathogens, and, consistent with this, we found significant anti-TIGR4 IgA titers in 
the lung homogenates from i.n. colonized mice (Figure 3-1B bottom panel). In 
both serum and lung homogenates, antibody titers achieved by i.n. colonization 
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(filled circles) were comparable to those in i.p. immunized mice (open circles). 
Further analysis of bronchoalveolar lavage fluid (Figure 3-1C “lung washes”) 
confirmed high IgG and IgA titers in the lungs of i.n. colonized mice against all 
the pneumococcal antigens tested in this study. Anti-PPS antibodies in the serum 
were expected given the evidence that significant titers of anti-PPS antibodies 
can develop in unvaccinated adults as a consequence of natural intranasal 
colonization [6]. Interestingly, we also found high titers against PC, a common 
pneumococcal surface component that has been shown to offer serotype-
independent protection against systemic disease [13]. The fact that protection 
against i.t challenge of previously nasopharygeally colonized mice positively 
correlates with high antibody titers suggest that antibodies may be critical for 
protection.  
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100 antibody units in this thesis contain approximately 
• 90 ng of anti-PC IgA antibody/ul of mouse serum.  
• 278 ng of anti-mouse IgA antibody/ul of mouse serum 
• 417 ng of anti-mouse IgG antibody/ul of mouse serum 
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Antibody responses in i.n. colonized mice are enhanced after i.t. 
challenge. 
 To test whether enhanced antibody responses in i.n. colonized mice 
correlated with protection from lethal infection, we analyzed the sera and lung 
homogenates of mice at the time of i.t. challenge as well as two weeks after 
challenge (Figure 3.2). At the time of challenge, i.e. three weeks after i.n. 
colonization, both serum and lung samples contained significant anti-
pneumococcal IgG and IgA as expected (Figure 3.2A and B). IgG against 
whole pneumococci and IgA against all antigens tested were significantly higher 
two weeks after i.t. challenge compared to the pre-challenge antibody units. 
Similarly, IgA levels in the lung homogenates were higher (though not 
statistically different for anti-PPS) in i.n. colonized mice that had been i.t. 
challenged (Figure 3.2B, bottom panel). Therefore, our data suggest that robust 
antibody responses generated by i.n. colonization are significantly boosted upon 
i.t. challenge.  
 Since antibodies appear to play a role after i.n. colonization and i.t. 
challenge, we next tested whether B cells are required for post-colonization 
protection, we subjected wild-type or B cell-deficient µMT-/- and JH -/- mice to 
nasopharyngeal colonization (Figure 3-3A). µMT-/- mice lack heavy chain of mu 
class, and consequently have no membrane bound IgM although some B cells 
may be produced through C chains. JH -/- mice lack heavy chain joining region 
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and lack mature B cells [65]. As shown in table 2-1 in the last chapter, only about 
60% of the B-cell deficient mice survive i.n. colonization. Therefore, we started 
with a larger group of mice and used 6 µMT -/- or 10 JH -/- survivors of i.n. 
inoculation for subsequent i.t. challenge. As expected, the surviving  µMT -/- and 
JH -/- mice displayed no antibody responses after colonization and challenge (data 
not shown). Upon i.t. challenge, wild-type mice survived at an expected rate of 
>80% (filled circles) whereas the survival rates of both µMT -/- (17%, p=0.003; 
open squares) and JH -/- mice (0%, p<0.001; filled diamonds) were significantly 
lower, demonstrating that B cells and antibodies are critical for colonization-
induced protection from i.t. challenge.  
 Given the essential role of antibodies in post-colonization protection from 
i.t. challenge, we next tested whether serum antibodies were sufficient to offer 
protection in naïve mice (Figure 3-3B). Pooled sera from naïve or i.n. colonized 
mice were adoptively transferred by i.p. injection into naïve wild-type mice and 
the recipients were challenged i.t. The survival rate of naïve sera recipients (open 
triangles) was 20%, identical to that of mice that received no serum (filled 
diamonds). Remarkably, sera from i.n. colonized mice (filled circles) conferred 
protection in 70% of the recipients upon i.t. challenge. This level of protection by 
immune sera was significantly above naive sera (p=0.030) or no sera controls 
(p=0.012).  
74
 Serum of i.n. colonized mice likely contain antibodies against several 
pneumococcal antigens, and we asked whether antibodies to one defined 
antigen is sufficient for similar protection. Given high antibody titers against 
phosphorylcholine (PC) following i.n. colonization (Figure 3-1) and its proven 
ability to provide protection from systemic challenge against various strains of 
pneumococci [62], we tested whether anti-PC antibodies were sufficient to 
protect against i.t. challenge. Accordingly, mice were treated with 50ug of 
monoclonal antibodies against PC (“α-PC-mAb”) 24 hours prior to i.t. challenge 
(Figure 3-3C). Naïve mice that received IgG isotype anti-PC by i.p. injection 
(open squares) had a survival rate of 70%, a significant increase from  control 
mice, which uniformly suffered lethal infection (filled triangles, p=0.017). Our 
results indicate that antibodies are sufficient for protection against i.t. challenge 
and that IgG isotype alone may be sufficient.  
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IgA significantly contributes to but is not absolutely required for post-
colonization protection. 
Significant IgA titers were present in the lungs of i.n. colonized mice 
(Figure 3-1 B and C), suggesting that IgA may be an important mechanism of 
protection. Therefore, we tested whether IgA was critical or sufficient for 
protection from i.t. challenge following i.n. colonization. First, we found that 
similar to α-PC-mAb (IgG), an anti-PC IgA isotype monoclonal antibody given i.v. 
also conferred protection, i.e., 80% survival, from i.t. challenge significantly (p = 
0.004) above control mice (Figure 3-3 C, filled diamonds). This result is 
consistent with the hypothesis that IgA isotype contributes to protection against 
otherwise lethal i.t. pneumococcal challenge.  
To test whether IgA responses elicited upon i.n. colonization are critical for 
protection, we subjected IgA-deficient mice to the same i.n. colonization and i.t. 
challenge procedure (Figure 3-4). After i.n. colonization, IgA-/- mice were able to 
generate pneumococcal-specific IgG titers (Figure 3-4 A, filled diamonds) 
indistinguishable from wild-type mice but, as expected, no detectable IgA 
antibodies (open squares). Whereas none of the naïve mice (Figure 3-4 B, filled 
triangles) survived i.t. challenge, 56% of IgA-deficient mice survived (open 
circles, p=0.022) Nevertheless, the survival rate of IgA-/- mice was marginally 
(p=0.046) lower than that for wild-type mice (88%; filled circles). These results 
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suggest that that IgA contributes to but is not absolutely required for post-
colonization protection.  
79
 
100 antibody units in this thesis contain approximately 
• 90 ng of anti-PC IgA antibody/ul of mouse serum.  
• 278 ng of anti-mouse IgA antibody/ul of mouse serum 
• 417 ng of anti-mouse IgG antibody/ul of mouse serum 
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T cells contribute significantly to anti-pneumococcal antibody responses 
and subsequent protection from intratracheal challenge.  
T-independent responses are sufficient to provide protection against 
systemic infections following immunization with pneumococcal polysaccharides 
[1, 2]. We also found that T cells are not required to prevent lethal infection 
following i.n. colonization (Table 2-1). However, given the requirement for CD4+ T 
to prevent re-colonization of the nasopharynx following i.n. colonization [44], it is 
possible that T cells are required to protect mice against i.t. challenge. Therefore, 
we analyzed the ability of T cell-deficient TCR βxδ-/- mice to generate a protective 
response after nasopharyngeal colonization (Figure 3-5 A top panel), or, as a 
control, after i.p. immunization with whole killed bacteria (Fig 3-5 A bottom 
panel). Consistent with previous reports [1], T-cell independent responses 
offered 100% protected from i.p. challenge after i.p. immunization with heat-killed 
whole bacteria, indicating that T cells play no discernible role in generating a 
protective response after i.p. immunization (Figure 3-5 A bottom panel, 
p=0.001). After i.t. challenge, 83% of i.n. colonized wild-type mice (filled circles) 
and 10% of naïve mice (open triangles) survived, as expected from our previous 
findings. T cell-deficient mice that had been i.n. colonized displayed a survival 
rate of 40%, a rate that was significantly (p=0.022) reduced from i.n. colonized 
wild-type mice and higher, and not significantly better than naïve wild-type. 
These results suggest that, in contrast to the generation of an immune response 
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following i.p. immunization, capable of protection from systemic challenge, full 
protection from pulmonary challenge following i.n. colonization requires T 
lymphocytes. These findings highlight an important difference in protective 
mechanisms among different pneumococcus immunization and challenge 
models. 
To further explore the observed reduced survival of TCR βxδ-/- mice, we 
measured anti-pneumococcal antibody titers in sera of these mice either just 
before or 60 hours after i.t. challenge. Just before challenge (Figure 3-5 B), 
serum IgM levels binding to all antigens tested in TCR βxδ-/- mice (filled triangles) 
were similar to those in wild-type mice (open circles), whereas serum anti-PPS 
and anti-PC IgG and IgA were moderately but significantly reduced. The antibody 
titers at 60 hours post i.t. challenge (Figure 3-5 C) were also moderately 
reduced, particularly in IgG titers to whole bacteria, to PPS and to PC. Taken 
together, our findings imply that T cells contribute moderately and significantly to 
anti-pneumococcal antibody responses, including to those antigens such as PPS 
and PC that are considered to be prototypic T-independent antigens. Given the 
extensive evidence that antibody responses to these antigens contributes to 
protection from systemic disease, it seems likely that the moderate defect in the 
humoral response to pneumococcus is at least partially responsible for the 
increased susceptibility of T-deficient mice to i.t. challenge after i.n. colonization.  
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CD4+ T cells play an important role at the time of challenge in the 
protection against nasopharyngeal recolonization induced by i.n. inoculation 
(Malley, Trzcinski et al. 2005). To begin to determine whether CD4+ T cells in 
particular, at the time of challenge, are important for protection against i.t. 
challenge, we depleted CD4+ lymphocytes at the time of such challenge by 
treating mice with 0.5ug of anti-CD4 monoclonal antibody two days before, one 
day before and one day after challenge. Consistent with previous studies, this 
procedure depleted more than 98% of CD4+ cells (Figure S-3). Depletion of 
CD4+ cells did not compromise protection since mice treated with anti-CD4 
antibodies had a survival rate comparable to (and in fact somewhat greater than) 
that of wild-type (90% vs. 75% respectively, Figure 3-5 D). Therefore, in contrast 
to the nasopharyngeal re-colonization model [42], we found that CD4+ T cells are 
not required at the time of i.t. challenge to confer protection.  
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CD4+ T cells are dispensable for protection against i.t. challenge after i.n. 
colonization of BALB/c mice.  
Though not required at the time of challenge, CD4+ T may be important for 
establishment of protective responses upon i.n. inoculations. Due to the local 
availability of BALB/c but not C57BL/6 CD4-/- mice, we performed a genetic test 
of this hypothesis in the BALB/c rather than the C57/Bl6 background.  BALB/c 
CD4-/- mice were i.n. colonized and i.t. challenged in parallel with i.n. colonized 
wild-type mice or wild-type naïve controls (Figure 3-6). Interestingly CD4-/- mice 
(open squares) had about 73% survival compared to 100% of wild-type mice 
(filled circles, n.s.) and 20% of naïve mice (open triangles, p=0.04).  
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Anti-pneumococcal antibodies and the immunological protection elicited 
by intranasal colonization are long-lived. 
 To determine if i.n. colonization induces  pneumococcal antibodies that 
are long lived, serum samples of the i.n. colonized mice at 10 (circles) and 18 
(triangles) weeks after colonization were titered for pneumococcal-specific IgG 
(Figure 3-7 A, left panel) and IgA (right panel). Both isotypes remained high for 
at least 18 weeks post colonization. To determine whether the stable antibody 
titers correlated with protection, i.n. colonized mice were challenged i.t. at 10 
weeks post i.n. colonization (Figure 3-7 B). Seventy percent of the colonized 
mice (open circles) survived challenge, compared to survival of none of the naïve 
mice (filled triangles) (p=0.001), suggesting that protection afforded by 
colonization-induced antibodies was long lasting.  
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Peritoneal B1 cells are not sufficient for colonization-induced protection 
from i.t. challenge.  
 B1 cells are a subset of B lymphocytes that can rapidly mount long-
lasting IgM responses to T-independent antigens [20, 22] B1 cells are numerous 
in the peritoneal cavity and, in mice, a population of peritoneal B1 cells, B1b 
cells, play a role in protection against S. pneumoniae systemic disease following 
polysaccharide or heat-killed immunization [1]. In order to determine if B1b cells 
mediate post-colonization protection in our model, we transferred approximately 
2x106 total, un-fractionated peritoneal cells into Rag1-/- mice lacking B and T 
lymphocytes. One week after the transfer, Rag1-/- recipients were i.n. colonized 
and i.t. challenged as previously described (Figure 3-8). We showed in Table 2-
1 in the last chapter that nearly 70% of naive Rag-/- mice succumb to lethal 
infections resulting from i.n. inoculation. Interestingly, compared to naïve controls 
(inverted triangles), Rag-/- mice that received peritoneal cells survived the i.n. 
inoculations better (100% (p=0.005) and 70% (non-significant) in experiment # 1 
and 2, respectively) (Figure 3-8 A). However, upon i.t. challenge, i.n. colonized 
Rag-/- were poorly protected at 20%. Our data suggests that cells in the 
peritoneal cavity may help limit i.n. colonization in naïve mice but that they were 
not sufficient for protection against i.t. challenge following i.n. colonization.  
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 We next determined whether lack of protection by peritoneal cells was 
specific to responses elicited by i.n. colonization (Figure 3-9). To test this, we 
immunized some Rag-/- recipients with heat-killed S.p. TIGR4 and challenged i.t. 
or i.p. (Figure 3-9A). Remarkably, peritoneal cells were able to offer protection 
against these challenges in i.p.-immunized Rag-/- mice. The increased survival 
correlated with the ability of i.p. immunization (Figure 3-9B) to elicit more robust 
antibody responses in Rag-/- recipients. Consistent with peritoneal B1 cells 
mediating IgM responses, we found significantly higher IgM titers in the serum of 
i.p.-immunized recipients (open squares) compared to i.n-colonized counterparts 
(filled circles). IgA titers were also significantly different, though to a lesser extent 
and IgG titers were comparable between i.p immunization and i.n colonization.  
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Radiation-resistant plasma cells contribute significantly in colonization-
induced protection from i.t. challenge.  
Long-lived antibody responses can be facilitated by constant re-stimulation of 
memory B cells (Bmem) with antigens or by long-lived antibody secreting cells 
(ASC). The former scenario is unlikely in our system because at the end of the 
colonization procedure, mice were treated with rifampicin to clear the colonizing 
bacteria (see materials and methods). In addition, the fact that CD4+ T cells were 
not required at the time of challenge suggests that traditional T-dependent 
memory responses are not the sole mechanism of protection. Therefore, we 
hypothesize that long-lived antibody producing cells that reside in the bone 
marrow may be required for protection. To begin addressing the relative roles of 
memory B cells and long-lived ASC, we first used mice deficient in CD93, a 
receptor shown to be required for persistence of long-lived ASC in the bone 
marrow [66]. Intratracheal challenge of the nasopharyngeally colonized CD93-/- 
mice resulted in death in 60 hours or less (Figure 3-10A). All of the i.n. colonized 
CD93-/- mice (filled squares) succumbed to lethal infection following i.t. challenge 
unlike colonized wild-type controls (filled circles), which displayed an 80% 
survival rate. With the exception of the levels of anti-PC IgM, reduced survival 
also correlated with fewer number of anti-pneumooccal antibody secreting cells 
in the bone marrow at the time of challenge (Figure 3-10B). Statistical 
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significance of the ELISPOT data was not calculated because of the large 
variation in the number of antibody secreting cells in wild-type mice and the fact 
that only two mice were used per group.  
 Our results with CD93-/- mice suggested that plasma cells in the bone 
marrow may be important in providing long-lasting antibody responses after i.n. 
colonization. Nevertheless, we could not rule out the possibility that CD93-/- mice 
may have defects in the innate (and other) immune responses. It has been 
proposed that CD93 functions as a regulator of inflammation [67]. Our results 
showed that passive transfer of immune sera from i.n. colonized wild-type mice 
protected CD93-deficient recipients at a reduced level compared to wild-type 
recipients (Figure 3-10C) although the difference did not achieve a statistical 
significance.  
 Therefore, we used an independent method to test the role of long-lived 
plasma cells (Figure 3-11). To this end, we utilized sub-lethal whole body 
irradiation, which compromises the ability of memory cells to differentiate into 
antibody-secreting cells but spares long-lived actively secreting plasma cells [2]. 
Mice were subjected to sub-lethal radiation 3 weeks after i.n. colonization and i.t. 
challenged two weeks later. Sub-lethal irradiation caused a reduction in the 
number of ASC in the bone marrow, although the number of antibody secreted 
cells persisted above the background level found in naïve mice (Fig 3-11 B). 
However, such reduction was not apparent in the spleens (Fig 3-11 C). Upon i.t. 
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challenge, naïve mice had an expected low survival rate of 20% (Figure 3-11 A, 
filled triangles), whereas the survival rate of sub-lethally irradiated mice (open 
squares) was ~62% (p=0.008 vs. naïve controls). Furthermore, this survival rate 
was not statistically different from the 78% survival rate on non-irradiated i.n. 
colonized mice (filled circles) tested in parallel. These results suggest that radio-
resistant cells offer significant protection in our model.  
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Discussion  
 Within the human population, the low incidence of rare S. pneumoniae 
invasive diseases relative to the high carriage rate suggests that intranasal 
colonization may provide a degree of protection against serious invasive 
infection. Understanding the mechanisms of potential natural protection has 
implications for improved vaccines. In murine models, there is strong evidence 
that i.n. colonization with wild-type or attenuated live pneumococci induce 
protective responses against re-colonization or invasive challenge [30, 42, 43, 
49]. However, mechanisms of protection and cellular requirements remain largely 
unknown and vary depending on site of re-challenge [32]. As described in 
Chapter 2, we established a C57BL/6 murine model in which a series of i.n. 
inoculation of wild-type pneumococcus resulted in protection from i.t. challenge, a 
mimic of aspiration that apparently leads to pneumonia in humans.  
 Previous studies used i.n. colonization by live-attenuated mutants to 
protect against invasive intranasal challenge [30, 49]. In these studies, intranasal 
challenge of anesthetized mice with a relatively large volume (50ul) of S. 
pneumoniae results in aspiration of bacteria into the lungs that later translocate 
into the bloodstream, and antibodies were required for protection against lethal 
sepsis. In the current study, we found that i.n. colonization induces the 
production of significant serum and mucosal pneumococcal-specific antibodies. 
µMT-/- mice, which are incapable of generating a humoral response were 
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incapable of acquiring protective immunity, and serum transfer from immune to 
naïve mice suggested that the anti-pneumococcal antibodies were sufficient for 
protection.  
 In Chapter 2, we found that the degree of cross-protection among strains 
expressing different capsular serotypes varied considerably.  In fact, high titers of 
anti-capsular antibodies observed upon i.n. colonization are consistent with the 
suggestion that serotype-specific responses are an important component of 
protection against i.t. challenge. We do not know whether the cross protection we 
observed in the studies described in Chapter 2 correlates with the degree of 
antigenic crossreactivity between the various strains analyzed. Further 
experiments are necessary to test the primacy of anticapsular antibody 
responses in this model.  
 We found that i.n. colonization induces robust titers of not only IgG but 
also IgA, an isotype important for protection of the mucosa [68]. Although high 
IgA titers have been observed upon i.n. colonization with attenuated 
pneumococci [30, 49], requirement for IgA to protect against lung infection has 
not been tested. We show here that IgA-deficiency led to decreased survival 
upon i.t. challenge but that IgA was not absolutely required for a partially 
protective response. Our findings are consistent with existing evidence that IgA 
responses may be important during S. pneumoniae infection. Serum IgA is 
capable of mediating killing of S. pneumoniae by complement and phagocytes 
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[69], but S. pneumoniae encodes IgA1 protease to compromise humoral IgA 
responses [70]. In mice, the inability to produce IgA or transport IgA onto 
mucosal surfaces compromises protection against nasopharyngeal re-
colonizaiton following i.n. immunization [71]. We speculate that IgA-/- mice suffer 
higher than wild-type bacterial burden in the lungs, leading to more rapid breach 
of mucosal barrier and subsequent escape of bacteria into the bloodstream. The 
partial nature of the defect of IgA-/- mice to survive pneumococcal challenge may 
reflect the production of other serotypes such as IgG.   
 The high anti-PC titers elicited upon i.n. colonization suggests that it 
may be a key antigen in our observed protection against i.t. challenge. In fact, we 
showed that anti-PC monoclonal antibodies of either IgG or IgA isotype were 
sufficient to protect against i.t. challenge. Since PC is a common antigen in all 
pneumococcal strain, and anti-PC antibodies may contribute to the partial cross-
serotype protection we observed after challenge with a strain expressing a 
capsular serotype different from the colonizing strain.  
 Antibodies were not required to protect against re-infection of the 
nasopharynx after i.n. colonization with a wild-type pneumococci [42]. Thus, our 
observation that protective antibody responses were necessary to protect against 
i.t. challenge indicate unique mechanisms required to protect against intranasal 
colonization and more invasive lung challenge. Upon growth in the lung, S. 
pneumoniae can induce tissue injury by toxin activity [72] or overwhelming 
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inflammatory responses [73], which in turn promotes bacterial invasion into the 
bloodstream. Infection of the lungs by S. pneumoniae is, therefore, results in 
potential growth of bacteria both in the lungs and in the bloodstream. As such, a 
successful control of lung infections might require a combination of protective 
responses, including both cellular effectors that have been shown to control 
bacterial burden in the mucosal surfaces [45] and humoral responses that can 
provide opsonizing and neutralizing activities. On the other hand, antibody 
independent function of T cells, particularly IL-17A production by CD4+ T cells, 
protect against re-colonization at the nasopharynx after i.n. colonization [42, 74] 
 A significant contribution of T cells was also observed in our current 
study. T-cell deficient TCRβxδ-/- mice generated lower anti-pneumococcal 
antibody titers and survived at a significantly lower rate than wild-type controls 
upon i.t. challenge. This is in contrast to systemic immunization models where 
others have shown (and we have confirmed here) that T-independent responses 
are sufficient to protect against bloodstream challenge [1]. Our results showed a 
T-dependent component in protection of the lungs. Similarly, T cells are also 
important in colonization-induced protection against nasopharyngeal colonization 
[40, 42, 44]. Taken together, the results may explain the apparent partial efficacy 
of current T-independent PPS vaccines to protect against pneumonia [75]. T 
cells, since they are able to activate antimicrobial peptides and help produce IgA 
isotype, may be required for efficient protective responses at the mucosal 
surfaces.  
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 Although T cells were important in our model, CD4+ T cells were not 
required at the time of i.t. challenge to prevent lethal infection. Therefore, it is 
unlikely that TH17-mediated cellular responses are critical to protect against 
lethal infection resulting from i.t. challenge. It is possible that CD4+ T cells are yet 
important to establish protective responses following intranasal inoculations, and 
we tested this hypothesis using CD4-/- mice on the BALB/c background, which 
were not significantly compromised for colonization-induced protection against i.t. 
challenge. However, we have shown that degree of protection induced by 
nasopharyngeal colonization of BALB/c mice was superior to that of C57BL/6 
mice, so it will be informative to analyze CD4-/- or MHCII-/- mice on C57BL/6 
background and compare the results to TCRβxδ-/- mice.  
 It has been suggested CD8+ but not CD4+ T cells playing a role in 
preventing bacterial dissemination and lung inflammation during infection by 
serotype 3 S. pneumoniae [76], though relative roles of T helper cells may be 
dependent on pneumococcal serotype [77]. In future studies, it will be informative 
to determine if a genetic deficiency of CD8+ T cells, or depletion of these cells at 
the time of challenge, compromise the ability of i.n. colonized mice to resist lethal 
i.t. infection with our serotype 4 strain. 
 The result that CD4+ T cells were not required at the time of i.t. 
challenge suggests that CD4-dependent memory B cell recall responses were 
not essential for protection. Nevertheless, protection afforded by i.n. colonization 
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was long-lasting. In particular, IgA and IgG responses following i.n. colonization 
persisted for at least 18 weeks in our studies. Given the rifampacin treatment of 
i.n. colonized mice is predicted to eliminate colonizing bacteria, it is unlikely that 
the long-lived antibody responses were mediated by continuous antigen 
exposure. Long lived plasma cells, which continuously secret antibodies for 
months to years in the absence of circulating antigens, have been implicated in 
protection from systemic pneumococcal diseases [2, 23]. Long-lived plasma cells 
are thought to be generated and maintained in an T-independent manner 
because long-lasting antibodies specific to pneumococcal capsule are observed 
after immunization with T-independent antigen polysaccharides. Upon adoptive 
transfer, radioresistant bone-marrow plasma cells are sufficient to confer 
protection in naïve mice against bloodstream infection with S. pneumoniae [2]. 
Therefore, we tested the role of long-lived plasma cells in our system and found 
that radio-resistant lymphocytes, likely corresponding to ASC in the bone 
marrow, provided significant contribution to protection. However, protection was 
partially diminished by sub-lethal irradiation, suggesting a role for radio-sensitive 
cells in protection or irradiation-induced altered cytokine responses in its 
compromise [78]. We are currently investigating if ASC in the bone marrow that 
develop after i.n. colonization are sufficient to protect against i.t. challenge.  
 In conclusion, we have shown using an inbred mouse model that i.n. 
colonization by S. pneumoniae elicits protective responses against otherwise 
lethal systemic and lung infections. The protective mechanisms are distinct from 
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T-independent responses achieved by PPS immunization or antibody-
independent responses required preventing nasopharyngeal re-colonization 
following i.n. colonization with wild-type pneumococci. Our results demonstrated 
that antibodies are essential in protecting lethal lung infection following i.n. 
colonization, and suggested long-lived plasma cells contribute to long-lasting 
protective responses. Further characterization of lymphocytes, plasma cells and 
secreted effectors that are critical for colonization-induced protection would 
enhance our understanding of how many individuals are naturally protected 
against invasive pneumococcal diseases and aid in designing better preventative 
measures for at-risk individuals.   
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Chapter IV 
Discussion 
 S. pneumoniae is a common commensal of the human nasopharynx: 
about 40% of the human population carries S. pneumoniae asymptomatically and 
children under 3 years of age have the highest carriage rates compared to other 
age groups [3]. It is likely that natural exposure to pneumococci in the 
nasopharynx primes the immune system because high titers of antibodies 
against pneumococcal polysaccharides are found in the serum of unvaccinated, 
healthy individuals [16]. Rates of colonization and invasive diseases also 
diminish with age, consistent with the suggestion that repeated exposure to 
pneumococci may lead to protection against subsequent encounter with the 
bacteria. Disease rates rise again in persons over 65 years of age, which has 
been attributed to age-related defects in cytokine and B cell responses [58, 59, 
79]. Collectively, evidence suggests that intranasal colonization by S. 
pneumoniae may elicit immune responses that may protect healthy, middle-aged 
individuals against invasive infection, and that protection may require both 
humoral immunity as well as cellular responses initiated by cytokines. A better 
understanding of this natural protection induced by intranasal colonization has 
implications for preventative strategies in high-risk individuals. 
 Pneumonia is the most common form of S. pneumoniae invasive disease 
[7]. Overwhelming bacterial loads in the lungs can lead to disruption of tissue 
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integrity due to the direct action of pneumococcal toxins such as pneumolysin 
[72] and the damaging effects of inflammation. Subsequent invasion of bacteria 
into the bloodstream poses an even greater threat since the pneumococcal 
capsule prevents efficient complement-mediated opsonophagocytosis and 
predisposes to overwhelming sepsis [80]. Prevention of the life-threatening 
aspects of pneumococcal lung infection, therefore, requires both local responses 
in the lungs to limit bacterial burden and inflammation, as well as systemic 
responses to eliminate bacteria translocated into the bloodstream. Accordingly, a 
complex interaction of host immune responses likely exists to prevent and control 
invasive pneumococcal disease.  
 While the mechanisms of protection by nasopharyngeal colonization with 
wild-type pneumococci that prevent re-colonization at that site have been 
extensively studied [42, 43, 74], we expected that postcolonization resistance to 
invasive lung infection, which is largely unexplored, might be mechanistically 
different. Although two studies have addressed protection from invasive 
pneumococcal disease after colonization by attenuated strains [30, 49], no 
published studies have investigated protective responses against lung challenge 
following i.n. colonization with wild-type pneumococci, i.e., strains that are not 
attenuated by genetic manipulation. We reasoned that use of wild-type 
pneumococci would better mimic natural carriage of S. pneumoniae in humans 
and allow for characterization of the putative protective responses that is 
induced. The S. pneumoniae strain utilized in these studies, TIGR4, expresses 
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capsular serotype 4, a type commonly found among pneumococcal strains in 
human nasopharynx. TIGR4 can cause stable nasopharyngeal colonization, and 
10 days after intranasal inoculation with TIGR4, bacteria have been recovered 
from both the lungs and nasopharynx of mice [55], suggesting that serotype 4 is 
capable of (transient) invasion into deeper tissues after i.n. inoculation. Indeed, 
TIGR4 is capable of lethal invasive disease in mice [42, 81].  
In the studies described in Chapter 2, we established a murine model in 
which i.n. inoculation with wild-type TIGR4 resulted in significant protection 
against subsequent lung infection. In Chapter 3, I describe investigation into 
which specific components of the immune system play a role in colonization-
induced protection against intratracheal challenge. 
Role of antibodies during intranasal colonization  
 We showed here that antibody-deficient µMT-/- mice were more 
susceptible than wild-type mice to lethal infection resulting from intranasal 
colonization. This defect is likely associated with IgM isotype because 1) sIgM-/- 
mice that are lacking the secreted form are as susceptible as antibody-deficient 
mice (Table 2-1) and 2) TCRβδ-/- mice that displayed wild-type levels of IgM but 
no detectable anti-pneumococcal IgG had a survival rate comparable to wild-type 
upon intranasal inoculation (Table 2-1 and Figure 2-1). Although antibodies play 
a limited role in clearance of intranasal carriage or in protection against 
subsequent re-colonization [43, 57], studies addressing their requirement in 
preventing lethal infection following intranasal colonization have been limited. For 
108
example, although i.n. inoculation of µMT-/- mice with a type 23F strain does not 
lead to invasive pneumococcal disease [57], this strain is of limited virulence in 
mice whereas the TIGR4 strain used in this study causes severe invasive 
disease [81]. Therefore, it is likely that even though antibodies are not required 
for eventual clearance of intranasal carriage, they are required to prevent deadly 
infections during intranasal colonization with highly invasive strains. 
 Given the compromised survival of sIgM-deficient mice (Table 2-1), it is 
possible that “natural antibody”, i.e. IgM in the serum of naïve mice, is important 
in limiting pneumococcal infection in naïve hosts. It has been shown that naïve 
mouse serum contains natural antibodies that recognize pneumococcal 
polysaccharides and phosphorylcholine and that can provide some level of 
protection against systemic pneumococcal disease [1, 13]. A subset of T-
independent B1 cells abundant in the peritoneum, B1a cells, are responsible for 
natural IgM that recognizes pneumococcal antigens [1]. Adoptive transfer of un-
fractionated peritoneal cells into Rag1-/- mice results in significantly increased 
survival upon i.n. inoculation in one out of two experiments (Figure 3-7A), 
suggesting that B1a cells might play a role in providing an important IgM 
response to pneumococcal antigens in naïve hosts [1].  In the future, determining 
whether transfer of purified B1a cells into immunodeficient Rag1-/- or antibody-
deficient µMT-/- results in an increase in the ~40% survival exhibited by these 
immunodeficient mice in response to i.n inoculation would further test the role of 
B1a cells in producing protective natural antibody. If natural IgM by B1a cells 
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plays protective roles in naïve mice, transfer of un-fractioned peritoneal cells from 
CD19-overexpressing (hCD19Tg) mice, which predominantly contain B1a cells 
[1], would enhance survival of Rag1-/- mice in response to i.n. inoculation. Finally, 
it would be informative to establish intranasal colonization in CD19-deficient 
mice, which have a severe reduction in the number of peritoneal B1a cells and 
do not contain anti-pneumococcal IgM in their naïve sera [1]. If natural IgM is 
important for protection against pneumococcal disease following i.n. colonization, 
CD19-deficient mice would be expected to have a survival rate similar to 
antibody-deficient mice.   
Influence of host strain on colonization-induced protection 
Whereas C57BL/6 mice required three i.n. exposures to establish 
protected responses, BALB/c mice uniformly survived i.t. challenge after two i.n. 
exposures (Figure 2-3). Although the genetic basis remains unclear, it has been 
previously demonstrated that compared to C57BL/6 strain, BALB/c mice survive 
long with fewer cases of bacteremia upon i.n. challenge with S. pneumoniae. In 
addition, BALB/c mice elicited more robust antimicrobial responses in the lungs 
after i.t. challenge [32]. Finally, in BALB/c mice, the majority of anti-
phosophorylcholine (PC) antibodies are associated with the T15 idiotype [82]. 
These T15+ anti-PC responses are 100 times more effective at protection 
against lethal pneumococcal infection than other idiotypes [61]. Our results 
showed that significant titers of anti-PC antibodies were generated upon i.n. 
colonization. It is possible that quantitative and qualitative differences in the anti-
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PC responses between C57BL/6 vs. BALB/c mice is responsible for the 
differences in protective responses observed here. In this thesis, we have 
focused on characterization of colonization-induced protection in C57BL/6 mice 
due to the availabiilty of a wide variety of knock out strains generated in this 
background.  
Role of antibodies during colonization-induced protection against i.t. 
challenge 
 Although natural IgM may be sufficient to limit spread of nasopharyngeal 
carriage in naïve mice, they are clearly not sufficient to protect against 
intratracheal challenge given that we showed that 85%-95% of naïve mice suffer 
lethal disease, including bacteremia, after that route of infection. Our results 
demonstrated an essential role for colonization-induced antibody responses in 
protection against lethal lung infection. A robust anti-pneumococcal antibodies is 
generated upon i.n. inoculation, and the ~50% of µMT-/- mice that survived i.n. 
colonization procedure succumbed to lethal infection upon i.t. challenge (Figure 
3-2A). In addition, immune sera from i.n. colonized mice or antibodies against the 
pneumococcal cell wall component phosphorylcholine were sufficient to protect 
naïve mice against i.t. challenge (Figure 3-2 B, C). Our results are in agreement 
with antibody-dependent protection against invasive lung challenge following i.n. 
colonization with a capsular polysaccharide mutant of S. pneumonia [30]. Given 
that colonization-induced protection against nasopharyngeal re-colonization is 
independent of antibody [43], our finding emphasizes that immune mechanisms 
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required to protect against non-lethal local colonization of the nasopharynx are 
distinct from those that protect against invasive lethal infection of the lung and 
bloodstream. Further experiments are necessary to determine if antibodies are 
required for accelerated pulmonary clearance for strains, such as serotype 19A 
strain Hungary, that colonize the lung but do not progress to lethal systemic 
infection.  
 Although a specific role for IgA during pneumococcal carriage and 
invasive disease in humans has yet to be documented [83] [84, 85], this 
secretory antibody is  thought to play an important role in protection of mucosal 
surfaces [68]. Secretory-IgA antibodies were required to protect against 
intranasal carriage following immunization of mice with pneumococcal 
polysaccharides or pneumococcal surface protein A (PspA) [71, 86], and robust 
anti-pneumococcal IgA responses have been observed after i.n. inoculation of 
attenuated pneumococcal strains [30, 49]. We utilized IgA-deficient mice to 
directly test for a requirement for IgA in defense against invasive pneumococcal 
pulmonary disease after nasopharyngeal colonization. Our results suggest that 
IgA is not absolutely required for but does significantly enhance protective 
responses elicited by nasopharyngeal colonization (Figure 3-3). The IgA-/- mice 
we infected were deficient not only in secreted IgA, but also in serum IgA, so we 
do not know if reduced survival was due specifically to the lack of IgA at mucosal 
surfaces. Future studies involving mice that lack polymeric Ig receptor (pIgR-/-), 
and consequently the ability to transport IgA to the mucosa lumen, could be used 
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to test if secreted IgA is required for control of pulmonary and/or systemic 
infection [71].  
Role of T cells during colonization-induced protection against i.t. challenge 
It is well established that T-independent responses are sufficient to protect 
against systemic challenge after immunization with capsular polysaccharides [1, 
2]. In our study, we found that T-indepnedent response are also sufficient for 
protection against systemic challenge following i.p. immunization with heat-killed 
pneumococci. In contrast, T cells contribute significantly to colonization-induced 
protection against i.t. challenge (Figure 3-4 A and B). Clearly, the means of 
protection from invasive pneumococcal disease differ depending on mode of 
immunization and/or challenge. Indeed, although immunization with 
pneumococcal polysaccharides have been shown in mouse models to protect 
against lethal bloodstream infections [1, 2], purified polysaccharide vaccine is not 
very effective in protecting humans against pneumococcal pneumonia [87-89]. 
This indicates that T-independent responses may not be sufficient to protect 
against invasive mucosal infections in humans. 
We found that post-colonization antibody titers in T cell-deficient mice 
were significantly lower than in wild-type mice (Figure 3-C). In particular, i.n. 
colonization elicited lower titers of IgG and IgA in T cell-deficient mice compared 
to wild-type controls. Our data suggest that T-cells aid in not only making robust 
antibody responses directed against pneumococcus but also in the class-
switching of colonization-induced antibodies. This enhancement in antibody 
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responses may account for the increased survival of wild-type compared to T 
cell-deficient mice. A classical means by which CD4+ T cells promote humoral 
immune responses is by cognate CD40L-CD40 interaction with B cells, inducing 
B cell differentiation into plasma cells. This interaction occurs both during the 
primary response and during “recall” responses when memory B cells 
differentiate into plasmablasts upon secondary encounter with the antigen. 
Although it is possible that CD4+ T cells facilitate a robust primary response to 
pneumococcal infection, we found that depletion of CD4+ T at the time of i.t. 
challenge did not compromise survival (Figure 3-4D), suggesting that CD4+ T 
cell-dependent reactivation of memory B cells was not required for protection.  
In addition to their direct, CD40L-mediated role in B cell activation, CD4+ T 
cells have other cellular functions to help enhance immune responses. Indeed, 
an antibody-independent requirement for CD4+ T cells has been demonstrated in 
colonization-induced protection against nasopharyngeal re-colonization [42]. 
Protection was mediated by IL-17A-producing CD4+ T cells, which have been 
shown to control infection by recruitment of neutrophils, activation of 
macrophages and increased expression of antimicrobial peptides during the early 
phases of mucosal infections [45, 90] and as reviewed in [91].  Increased levels 
of IL-17A have been observed upon lung infection following intranasal 
colonization with attenuated pneumococci [49] but our finding here that CD4+ T 
cells were dispensable at the time of i.t. challenge rules out the model that Th17 
cells provide critical antimicrobial function at the time of exposure.  
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Finally, it is possible that CD8+ rather than CD4+ T cells are critical for 
protection from i.t. challenge of i.n. colonized mice, In fact, although CD4+ T cell-
mediated inflammatory responses may prevent intranasal colonization, they may 
worsen the outcomes of invasive pneumococcal challenge by promoting 
inflammatory damage [92] [76]. Indeed, upon intranasal challenge, CD8-/-, but not 
CD4-/- or MHC II-/- mice, exhibited reduced survival compared to wild-type mice, 
and susceptibility was associated with more severe pulmonary inflammation [76, 
92]. A prediction is that CD4-/- mice would display no defect in mounting a 
protective response upon i.n. colonization, a result consistent with our studies of 
CD4-/- BALB/c mice (Figure 3-5). Given that we utilized the C57BL/6 strain 
background for nearly all of our studies, including T cell deficiency, a similar 
analysis with CD4-/- C57BL/6 mice, as well as with CD8-/- C57BL/6 mice, would 
likely prove informative.   
Role of B cell subsets during colonization-induced protection against i.t. 
challenge 
Our current study suggests that intranasal colonization elicits long-term 
protection against i.t. challenge (Figure 3-6). Identification of the lymphocytes 
that mediate this protection would inform the development of new vaccines. As 
noted above, given that CD4+ T cells are not required at the time of i.t. challenge, 
traditional memory cells that require CD4 help to exit a quiescent state are not 
likely to be required for protection. Thus, we considered two B cell subsets, B1b 
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lymphocytes or long-lived plasma cells, that might induce the long-lasting (10-
week) protection after i.n. colonization.   
B1b cells have been shown to be capable of T-independent, long-lasting 
IgM memory responses against B. hermsii and S. pneumoniae [1, 22], This B cell 
subset, like B1a cells, is enriched in the peritoneum. However, we found that 
peritoneal cells were not sufficient to protect against i.t. challenge after 
nasopharyngeal colonization, in contrast to the demonstrated ability of B1b cell to 
protect against systemic infection following polysaccharide immunization [1]. Our 
analyses revealed that after transfer of peritoneal cells, Rag1-/- mice produced 
more robust antibody responses after i.p. immunization with heat-killed bacteria 
than after i.n. colonization (Figure 3-8). The increased antibody responses 
associated with i.p. immunization correlated with better survival upon 
intratracheal challenge. Together, our results suggest that systemic 
immunization, rather than i.n. colonization, is more efficient at engaging B1 cells 
to mount protective responses. It is possible that compared to direct antigen 
delivery to the peritoneum, i.e., a compartment highly enriched for B1b cells, 
local colonization of the nasopharynx by pneumococcus primes B1b cells in the 
peritoneum with low efficiency.  
Long-lived antibody secreting cells (ASC) in the bone marrow have been 
reported to mediate protection against systemic challenge following immunization 
with a combination of pneumococcal polysaccharides and a CpG adjuvant [2]. 
Unlike traditional memory B cells, long-lived ASC continuously secrete antibodies 
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and do not require CD4-dependent reactivation. Since they do not require cell 
division to become active for effector functions, they are relatively resistant to 
irradiation. We showed that a significant portion of bone marrow cells retained 
the ability to secrete antibodies against pneumococcal antigens after whole body 
irradiation, and irradiated mice were still capable of survival of an i.t. challenge 
(Figure 3-10). Nevertheless, the protection was (though not significantly) 
reduced compared to non-irradiated (but colonized) controls, suggesting a role 
for radio-sensitive cells. Adoptive transfer of purified long-lived ASCs, identified 
and isolated on the basis of their expression of CD138, into B cell deficient mice 
would be required to rigorously demonstrate that they are sufficient for protection. 
Conversely, reconstitution of B cell deficient mice with CD138-depleted bone 
marrow cells is predicted to be incapable of conferring protection against i.t. 
challenge. 
Although studies have shown that long-lived plasma cells can be formed 
by immunization with T-independent antigens, it is unclear whether T cell 
deficient hosts will be able to generate these cells. In addition, depletion of CD4 
T cells at the time of challenge by intraperitoneal injection with anti-CD4 
antibodies may not eliminate CD4 T cells in the lungs. Therefore, future 
experiments in wild-type and T-cell deficient mice are necessary to determine if 
1) long-lasting antibody responses are achieved in T-cell deficient mice and 2) 
lymphocytes in the bone marrow of T cell deficient mice are able to generate 
anti-pneumococcal antibodies by ELISPOT assays.  
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Summary and Future Directions 
Intranasal colonization with wild-type S. pneumoniae elicited antibody-
mediated immune responses that protected against intratracheal challenge in 
mice. Serum and mucosal antibodies induced by i.n. colonization included both 
serotype-specific anticapsular and serotype-independent phosphorylcholine 
responses. Although monoclonal antibodies against phosophorylcholine were 
sufficient to confer protection, our results revealed that the ability of i.n. 
colonization to protect against i.t. challenge in a serotype-independent manner 
may depend on the virulence properties of the challenging strain. In the future, it 
would be interesting to analyze the antibody titers against conserved protein 
antigens, and whether robust cross-serotype responses can be elicited by i.n. 
colonization with live pneumococi. Contribution from T lymphocytes is required to 
achieve maximal antibody responses and survival, but protective responses do 
not require CD4+ T cells at the time of challenge. Whether other subsets of T 
cells are important during i.t. challenge or whether T cells are only required to 
establish initial protective responses remain to be more vigorously tested. A 
better understanding of the requirement for T cells may help identify the subsets 
of B lymphocytes are involved in protective responses. Based on our results that 
secondary responses did not require CD4+ T cells, we propose that T-
independent memory lymphocytes (functionally similar to B1b cells) or long-lived 
antibody secreting cells that do not require re-activation for secondary responses 
may be important. We are currently testing whether transfer of bone marrow 
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plasma cells from i.n. colonized mice confers protection in naïve, B cell-deficient 
mice. Although peritoneal B1 cells were not sufficient for colonization-induced 
protection, it would be informative to test whether these T-independent memory 
lymphocytes are generated and localized to mucosal surfaces (such as nasal-
associated lymphoid tissues NALT) upon i.n. colonization, and whether, by 
adoptive transfer, they are sufficient to confer protection.   
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